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Abstract 
Background: Genital Chlamydia trachomatis (chlamydia) is Australia’s most 
frequently notified communicable disease.  Associated costs have been estimated 
at between AUD$90-$160 million per year.  Chlamydia infection can lead to 
significant health complications including infertility in both sexes.  Public health 
surveillance data based on statutory notifications of cases provides 
epidemiological information useful in focussing chlamydia control efforts, 
however the data is limited without knowledge of testing patterns.  Clinical 
guidelines recommend annual tests for all sexually active people aged <30 years, 
and mathematical modelling demonstrates that large reductions in chlamydia 
prevalence are possible, provided there is adequate testing coverage. 
Aims: To investigate, in Tasmania: i) increasing rates of chlamydia notifications 
by demographic and risk profiles and behavioural characteristics; ii) rates of 
testing, retesting and test positivity; iii) the feasibility and usefulness of 
collecting population-level testing data; iv) potential clinical and behavioural 
influences on test positivity trends; v) whether testing effort is reaching strategic 
and clinical guidelines; vi) the role and type of healthcare provider in chlamydia 
testing. 
Methods:  Four Tasmanian datasets were analysed i) statutory data on all 
chlamydia cases notified from 2001-2010; ii) additional surveillance data 
collected on all notified cases of chlamydia from 2001-2010; iii) de-identified 
laboratory testing data collected from 2001-2010; and iv) linked laboratory 
testing data collected in 2012 and 2013.  Data were analysed by sex, geographic 
viii
location, indigenous status, sexual exposure, reason for testing and healthcare 
provider.  Testing patterns and positivity levels were examined and compared 
with data collected on notified cases. Population rates of testing and retesting, 
and test positivity were measured by sex, healthcare provider, geographic 
location and socioeconomic indicators.   
Results:  Females were more likely to have been tested as a result of screening, 
males as a result of presenting with symptoms or from contact tracing.  General 
practitioners identify the majority of cases.  Testing and retesting rates are lower 
than recommended levels. Testing and test positivity increased from 2001 to 
2010, most significantly in males and females aged 15-24 years; testing coverage 
was higher in females (21%) than males (6%) and test positivity was higher in 
males (16%) than females (10%). In 2012 and 2013, less testing and higher test 
positivity was found in areas of most disadvantage; retest rates at 3 months were 
low in males (10%) and females (14%), and retest positivity high in males (35%) 
and females (23%). 
Conclusions: 
Chlamydia infection is a significant public health issue.  After allowing for testing 
effort, an increase in notifications in young people was found in Tasmania. 
Testing levels are below those required to decrease chlamydia prevalence. 
Analysis of chlamydia testing, retesting and positivity trends can inform the 
development, monitoring and evaluation of prevention and control activities and 
improves the interpretation of notification data.   
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Introduction 
  2
1 Chapter 1 — Introduction 
1.1 Definition of chlamydia 
Chlamydiae are obligate intracellular bacteria with three species that most 
commonly cause human disease: Chlamydia psittaci, Chlamydia trachomatis, and 
Chlamydia pneumonia.  Chlamydia trachomatis serovars B and D through K are 
responsible for sexually acquired infections and perinatally transmitted 
infections of the neonate and infant (1).  Genital infection with C. trachomatis is 
the focus of this dissertation and will be referred to as “chlamydia”. 
1.2 Epidemiology of chlamydia 
1.2.1 Prevalence of chlamydia 
 Estimates reported by the World Health Organisation, based on data for 2005 to 
2012, show the pooled global prevalence of chlamydia to be 4.2% (95% UI: 3.7-
4.7%) in women and 2.7% (95% UI: 2.0-3.6%) in men (2).  Over 120 million new 
infections are estimated to occur globally each year (3), with the annual cost of 
treating acute infections and the complications they cause estimated to be US$10 
billion (4, 5).  Australian healthcare costs associated with chlamydial infection 
are estimated at between AUD$90-$160 million a year (6). 
In Australia, chlamydia prevalence estimates have been based on sub-
populations and therefore may not represent the true population prevalence (7).  
Reported prevalence varies across populations, with age the strongest predictor 
of risk (8). Vajdic et al’s (2005) systematic review of the prevalence of genital 
chlamydial infection in Australia between 1977 and 2004 included 40 studies of 
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50 populations, however only one of the included studies was population-based 
(based on a complete population), with the majority based on selected groups 
within populations.  They found prevalence to be higher in sexual health and 
related clinics than community-based estimates and a mean overall prevalence 
of 4.6%, but noted the over-sampling of high-risk groups (9).  Lewis et al (2012) 
more recently conducted a systematic review and meta-analysis of chlamydia 
prevalence in Australia from 1997-2011.  Seventy-six studies were included in 
their review but they reported limitations by heterogeneity within surveyed 
populations, and variations in sampling methodologies and data reporting.  Their 
analysis of five studies conducted post-2005 found a prevalence of 5.0% in 
women aged less than 25 years, and for men aged less than 30 years over the 
entire review period, a prevalence of 3.9%.  Prevalence was higher for those 
attending sexual health, family planning or youth clinics, in Indigenous males 
and females aged less than 25 years, and for rectal infection in men who have sex 
with men (10).  
1.2.2 Incidence of chlamydia 
Very few studies have examined the incidence rate of new infections due to the 
large population cohorts that would need to be tested at regular intervals (11). 
Walker et al’s (2012) study of 1,116 women aged 16 to 25 years attending 
general practice, family planning and sexual health clinics in three Australian 
jurisdictions (Australian Capital Territory, New South Wales and Victoria) found 
an incidence rate of 4.4 per 100 person years (95% CI: 3.3-5.9), consistent across 
type of healthcare provider (12).  In order to provide an estimate at a population 
level, Ali et al (2015) developed a Bayesian statistical approach to calibrate the 
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parameters of a decision-pathway tree against national data on notifications and 
tests conducted between 2001 and 2013.  They utilised a probabilistic tree to 
represent branches along which people could end each calendar year as either 
acquiring or not acquiring chlamydia infection, developing symptoms, being 
tested and treated and being notified as a case.  Each individual in the population 
was assigned probability of each step along the branch over the course of each 
year.  They based some probabilities on estimates in the literature, and others by 
fitting the model to data on the numbers of people tested and numbers 
diagnosed.  They used a stepwise Gaussian process model to allow annual 
infection and asymptomatic screening probabilities to vary yearly by age group 
and sex, with all other parameters fixed in time.   Their model suggested that the 
total number of people who acquired chlamydia in Australia over the 12 years 
increased by approximately 120%; the annual incidence estimate of 1.54% in 
2013 was a 90% increase over that in 2001 (0.8%); and that 356,000 people 
acquired chlamydia in 2013, which is 4.3 times the number of reported 
diagnoses (13).   
1.3 Public health significance 
Chlamydia is of public health significance because of the short and long-term 
sequelae associated with untreated infection, including urethritis, acute 
epididymitis and infertility in males, and cervicitis, urethritis, pelvic 
inflammatory disease, infertility, chronic pelvic pain and tubal pregnancy in 
females, and the association between chlamydial infection and increased 
transmission of other sexually transmissible infections.  A large proportion of 
infections are asymptomatic and as a result go undiagnosed, increasing the 
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likelihood of associated sequelae (3) (Table 1.1). The costs of treating subfertility 
due to chlamydia are high as tubal surgery and in vitro fertilization are 
expensive; and the cost of treating the complications of undiagnosed infection, 
including pelvic inflammatory disease and tubal infertility, are high both in 
psychosocial and financial terms (8). 
Table 1.1: Chlamydial infection - symptoms, sequelae and other factors 
Clinical manifestations (3, 8) Other (3) 
• Males: urethral discharge 
(urethritis), epididymitis, orchitis, 
infertility.  
• Females: cervicitis (infection of the 
neck of the womb), endometritis, 
salpingitis (fallopian tube 
inflammation), pelvic inflammatory 
disease, infertility, preterm rupture 
of membranes during pregnancy 
(‘waters breaking’ too soon), 
perihepatitis (inflammation of the 
liver coating); urethritis, chronic 
pelvic pain, tubal pregnancy.  
• Both sexes: proctitis (inflammation 
of the rectum), pharyngitis 
(inflammation of the throat), 
• It is estimated that up to 85% of 
women and over 50% of men are 
asymptomatic when infected with 
chlamydia (3, 14, 15). 
• The risk of infection from an 
infected male to his female partner 
is estimated to be 40% and from an 
infected female to male 30% (3). 
• If untreated, chlamydial infection 
may persist for years (3).  
Chlamydia is an important cause of 
both PID and tubal factor infertility 
(TFI).  Every 1000 chlamydia 
infections in women aged 16 to 44 
years gives rise to approximately 
171 episodes of PID; and 29% of 
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Reiter's syndrome (reactive 
arthritis. 
TFI is attributable to chlamydia 
(16). 
• Chlamydia infection facilitates the 
transmission of HIV infection in 
both males and females (17). 
 
 
1.4 Treatment of chlamydia 
Inexpensive and effective treatment is available for chlamydial infection (8), with 
current Australian guidelines recommending azithromycin or doxycycline as 
principal antibiotic treatment options (18).  For uncomplicated urogenital 
infections, a single 1g dose of azithromycin is recommended; and for anorectal 
infections, one week of doxycycline (100mg twice daily) (19).  Recent data has 
suggested that azithromycin may not be as effective as expected, with a wide 
range of treatment failure rates reported (5.8%-22.6%) (20).  Other studies, 
however, have demonstrated the efficacy of azithromycin as 97% (21).  
Differences between site of infection, immune response, drug pharmacokinetics, 
organism load, auto-inoculation from rectum to cervix in women and the genital 
microbiome are suspected to play a role in treatment success (19).  Randomised 
controlled trials are needed to evaluate azithromycin’s efficacy and to determine 
whether extended doses can be successful in the treatment of rectal (22) and 
pharyngeal (23) infections. 
  7
1.5 Public health surveillance  
Public health surveillance is the ongoing and systematic collection, analysis, 
interpretation and dissemination of data (Figure 1.1) (24, 25).  Health data is 
collected to identify trends, provide guidance for policy development and 
resource allocation, evaluate policy and the impact of disease control programs, 
provide early alert of disease outbreaks, describe the epidemiology of diseases 
and meet international and local reporting requirements (26). Often, 
surveillance data represents only a proportion (the ‘notified fraction’) of the total 
incidence of disease (Figure 1.2) and the notified fraction can vary over time 
(26). 
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Figure 1.1: Surveillance and response conceptual framework1 
 
Figure 1.2: Notified fraction 
1.6 Chlamydia surveillance 
National surveillance of chlamydial infections has been in place in Australia since 
1994 (27), and is an important component of public health management for 
chlamydia prevention and control (8).  The main form of chlamydia surveillance 
is passive reporting of cases to health departments in each Australian state and 
territory, by doctors and laboratories.  Along with other notifiable communicable 
diseases, health departments collect chlamydia notifications under their 
respective public health legislation and analyse the data for public health 
purposes (‘notification pathway’) (Figure 1.3).  In addition, the National Health 
Security Act 2007 (28) provides a legislative basis for and authorises the 
                                                        
1 Reproduced from Nsubuga P, White ME, Thacker SB, Anderson MA et al. Public Health 
Surveillance: a tool for targeting and monitoring interventions. In: Jamieson DT, Breman, J.G., 
Measham, A.R., editor. Disease Control Priorities in Developing Countries, 2nd Edition. 
Washington, DC: World Bank; 2006. 
Case
is notified
Test result is 
positive
Specimen is collected for 
testing
Person seeks medical care
Person is ill
Person is infected by organism
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exchange of health information between jurisdictions and the Australian 
Government Department of Health to allow for monitoring and reporting at a 
national level (26).  Public health surveillance data are managed based on their 
classification as sensitive, urgent or routine.  Sensitive data include notifications 
of a condition of particular interest to a jurisdiction at the time of notification 
(for example, Zika Virus Infection in 2016 due to its rapid spread worldwide and 
its potential association with microcephaly and neurological disorders (29)).  
Urgent cases are conditions that require fast public health action to prevent 
further transmission, such as measles.  Routine surveillance cases (such as 
chlamydia) are those conditions for which public health surveillance is primarily 
used for monitoring and reporting of trends and to inform and evaluate public 
health policy and interventions.  
Chlamydia surveillance data is used to plan and evaluate policies, prevention 
activities and management strategies and their effectiveness.  The greatest 
strength of the passive surveillance is its relative ease, being much less resource 
intensive than active surveillance (such as case follow up).  Nationally in 
Australia, jurisdictions routinely collect the date of specimen collection or 
diagnosis date, and the person’s sex, age and postcode of residence (27, 30) for 
each diagnosed case of chlamydia.  This enables national and local analysis and 
reporting of notifications by sex, age and geographic location (26, 27, 31).  
However, as chlamydia surveillance does not routinely collect data on negative 
tests (people who were tested for chlamydia but received a negative result), the 
limitations of passive surveillance data include the potential for bias by testing 
effort, for example the impact of increased or fluctuating patterns of testing over 
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time (9, 26), and the lack of ability to be able to monitor testing coverage in 
priority populations (30).  In addition, the passive surveillance data is de-
identified, that is, names and addresses are removed prior to the doctor or 
laboratory notifying the result to the local health department, therefore there is 
no ability to analyse the proportion of reinfections. Further, passive surveillance 
data does not provide any information on risk factors for acquiring infection, 
symptom status of notified cases, site of infection, Indigenous status, or 
behaviour characteristics of notified cases such as reason for testing, choice of 
healthcare provider or sexual exposure. 
Chlamydia notification data are not reliable indicators of population incidence or 
prevalence (9). Notifications are certain to be underestimates because the 
majority of tests are performed as a result of the presence of symptoms or 
through contact tracing partners of diagnosed cases, even though the majority of 
infections are asymptomatic (14, 15, 32). Chlamydia is equally transmitted in 
males and females (9), therefore the differences in rates of chlamydia 
notifications between males and females further highlights the caution required 
when interpreting the notification data (9).   
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Figure 1.3: Notification pathway 
 
1.7 Notification rates 
Chlamydia is the most frequently notified communicable disease in Australia and 
the number of reports of chlamydia infections have been increasing since the 
condition first became notifiable in 1994 (33).  Between 2007 and 2014, the 
number of notifications increased from 52,054 to 86,783, and the notification 
rate increased from 247 to 370 cases per 100,000 population (Figure 1.4).  
Young people aged 15 to 29 years comprise 80% of notified cases, and females 
are disproportionately represented.  The notification rates in the 15 to 29 year 
age range are significantly higher than those observed in the overall population. 
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Notification rates in young females are highest in those aged 15 to 19 and 20 to 
24 years, and in young males rates are highest in those aged 20 to 24 years 
(Table 1.2). 
 
Figure 1.4: Number of notifications and rate per 100,000 population, 
chlamydial infection, Australia, 2007 to 2014, by year  
(Source: Australian Government Department of Health, National Notifiable Diseases Surveillance System, available from: 
http://www9.health.gov.au/cda/source/cda-index.cfm) 
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Table 1.2: Chlamydia notification rates, males and females aged 15 to 29 
years, Australia, 2007 to 2012^   
    Notification rate per 100,000 population 
Age group Sex 2007 2008 2009 2010 2011 2012 
15-19 years Males 401 488 547 711 740 724 
  Females 1383 1566 1718 2064 2299 2202 
20-24 years Males 984 1030 1159 1328 1482 1483 
  Females 1595 1722 1788 2044 2228 2283 
25-29 years Males 604 663 671 786 841 866 
  Females 688 733 776 814 878 882 
^(Source: Australian Government Department of Health, National Notifiable Diseases Surveillance System, available from: 
http://www9.health.gov.au/cda/source/cda-index.cfm) 
 
1.8 Strategies to control chlamydia 
Transmission of chlamydia (as is the case for all sexually transmissible 
infections) is dependent on the probability of transmission of the pathogen from 
an infected to a susceptible individual, the rate of contact between infected and 
susceptible individuals, and how long the infection persists (34), therefore 
controlling chlamydia requires interventions  to reduce each of these factors (8).  
A range of activities are needed, including: primary prevention, such as patient-
level sexual health and relationship education, and population-wide information 
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and education; promotion of safer sex and condom use; and secondary 
prevention, including diagnosis and treatment of those with infection (8, 35); 
and contact tracing and treatment of infected partners (36).  Access to quality 
healthcare is crucial and the availability of a diverse range of services is required 
to provide comprehensive access to patients with, or at risk of, infection, 
including those in hard-to-reach population groups (8). .   
A particular public health goal for chlamydia control is reducing the duration of 
infection (8).  The asymptomatic nature of the majority of chlamydial infections 
results in infected persons being less likely to present for healthcare, thereby 
remaining infectious for a long period and having the potential to transmit the 
infection to their sexual partners.  Timely diagnosis and treatment is therefore 
an important component of public health strategies (8). 
Screening is an additional strategy for early detection and treatment of infected 
cases.  Evidence on the impact of screening on the prevalence of chlamydia 
infections at a population level is limited, as is the impact of the prevalence of 
complication in screened women (8).  The Australian Government has discussed 
the possible implementation of systematic screening and testing in the general 
population as a strategy to control chlamydia, however who to screen, how 
often, in what setting, and what type of screening program are all questions still 
under debate (37, 38, 39, 40).   
Surveillance activities are an essential component of public health responses to 
chlamydia infection, to provide information regarding the success of preventive 
and management activities at the population level (8).  Surveillance provides a 
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mechanism for reporting progress outcomes against strategic goals and supports 
policy development responsive to emerging trends (41). 
1.9 National strategy 
In response to the increasing rate of chlamydia notifications, the Australian 
Government’s Third National Sexually Transmissible Infections Strategy (the 
National Strategy) is designed to focus the healthcare community towards 
management and control of sexually transmissible infections (STIs), with the 
goal of reducing the transmission of and morbidity associated with STIs, and the 
personal and social impacts of infection (30).  Specific objectives and actions 
from the National Strategy include:  reducing disease incidence by increasing 
testing among priority populations; improving surveillance in priority 
populations; and improving methods of monitoring testing coverage.  Priority 
populations include people aged 15 to 29 years, particularly those aged 15 to 19 
years; Aboriginal and Torres Strait Islander people; and people residing in 
regional and remote locations (30). 
Priority actions under the Strategy include increasing the use, access to and 
accessibility of condoms amongst priority populations; promoting safer sex 
behaviours and regular testing; and building STI-related knowledge and skills in 
priority populations (30).  Public health initiatives aimed at influencing social 
determinants of health are an important component (8) as it is recognised that 
complex behavior change, such as increasing use of condoms, requires an 
integrated and sustained health promotion and disease prevention approach.  
The use of peer support and education models to target prevention activities is 
encouraged (30). 
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Improving the surveillance of chlamydia, particularly in priority populations, and 
improving methods to monitor testing coverage is vital to the success of the 
Strategy (30).  Surveillance will support the Strategy by providing data to 
identify and address emerging issues; evaluate health promotion, prevention, 
testing and treatment programs and activities to ensure they are effective; 
support research; and strengthen research translation to guide interventions 
(30). 
 
1.10 Tasmanian context 
Tasmania is an island state of Australia with a population of approximately 
512,000 people.  Tasmania’s unique approach to chlamydia surveillance 
combines passive and active surveillance.  Passive surveillance has been in place 
since 1997, with active surveillance commencing in 2001.   
Under the Tasmanian Guidelines for Notifying Diseases and Food Contaminants 
(42), laboratories are required to notify the Department of Health and Human 
Services (DHHS) all cases of Chlamydia trachomatis infection within five days of 
diagnosis.  DHHS receives the data passively from the laboratory, ie. without any 
routine follow up or actions to receive the data.  Failure of laboratories to notify 
may attract penalties under the Tasmanian Public Health Act 1997 (43).  Only 
laboratory confirmed cases of Chlamydia trachomatis infection are notifiable.  
Laboratory definitive evidence is defined as: 
Isolation of Chlamydia trachomatis 
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OR 
Detection of Chlamydia trachomatis by nucleic acid testing 
OR 
Detection of Chlamydia trachomatis antigen (44). 
Staff within the Communicable Disease Prevention Unit (CDPU) at the DHHS 
carry out active surveillance on notified chlamydia cases.  On receipt of a 
laboratory notification, CDPU forward the diagnosing clinician a questionnaire 
seeking additional information on their patient.   
The information collected from laboratories and treating doctors is shown in 
Table 1.3. 
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Table 1.3: Data on cases of Chlamydia trachomatis collected from 
laboratories and treating doctors in Tasmania 
Data fields collected from laboratories 
Data fields collected from treating 
doctor 
Name of disease Confirmation of case's sex 
Laboratory name 
Aboriginal or Torres Strait Islander 
status 
Laboratory number 
Reason for testing the patient - 
symptomatic or asymptomatic 
Specimen collection date If asymptomatic: reason for testing 
Method of diagnosis 
Whether case reports sexual contact 
with: a/ person(s) of opposite sex 
only; b/ person(s) of same sex only; 
c/ person(s) of both sexes; d/ 
unknown 
Surname - first two initials only 
Past history of chlamydia infection, if 
yes, year(s) of previous infection(s) 
First name - first two initials only 
Whether assistance with contact 
tracing is required 
Date of birth Any further comments 
Sex   
Suburb of residence in Tasmania   
Postcode   
Name of treating doctor   
Address of treating doctor   
Phone number of treating doctor   
Site of infection   
 
Further description and evaluation of the Tasmanian chlamydia surveillance 
system is provided as Attachment 1 to this Chapter. 
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1.11 Research aims 
In this thesis, I explore methods of meeting the key surveillance objectives 
defined under the National Strategy (22) and answering questions pertaining to 
priority populations.  Using the notification data and a unique population-based 
dataset collected on all chlamydia cases notified in Tasmania between 2001 and 
2010, and the results of all laboratory chlamydia testing data conducted from 
2001 to 2010 and in 2012 and 2013 in the same population, the specific research 
aims examined within this dissertation are: 
1. To investigate the increasing rates of chlamydia notifications by 
demographic profile, risk profile and behavioural characteristics, at a 
whole-population level. 
2. To explore the feasibility and usefulness of collecting population-level 
chlamydia testing data as a routine surveillance tool. 
3. To examine the chlamydia testing conducted in Tasmania at a whole 
population level, to determine test positivity trends. 
4. To explore the role and type of healthcare provider in meeting the 
strategic and clinical guidelines for chlamydia testing. 
5. To investigate potential clinical and behavioural influences on the 
positivity trends found in the chlamydia testing data of at-risk age groups. 
6. To report, for the first time in Australia, on the population rate of 
chlamydia testing and retesting in the priority population aged between 
15 and 29 years, to determine whether testing effort is reaching the 
strategic and clinical guidelines required to reduce chlamydia prevalence. 
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1.13 Attachment for Chapter 1: Description and evaluation of 
the Tasmanian chlamydia surveillance system 
1.13.1 Introduction 
The following method of describing and evaluating the Tasmanian chlamydia 
surveillance system was guided by the Center for Disease Control’s (CDC) 
guidelines for evaluating surveillance systems (based on the CDC’s Framework 
for Program evaluation in Public Health) (1).  Evidence to inform the description 
and evaluation was gathered through observation and stakeholder interviews.  
Stakeholders included the senior surveillance officer and data entry staff within 
the CDPU at DHHS, laboratory staff, and two groups who regularly use the data 
to inform their work (Tasmanian Sexual Health Service and Youth Health 
Services, DHHS). 
1.13.2 Objectives of the surveillance system 
The objectives of the Tasmanian chlamydia surveillance system are: 
• to enable monitoring of trends in infection, 
• to enable preventative public health measures to be implemented, 
• to enable evaluation of prevention activities; and 
• to assist with case management and treatment including contact tracing2 
as required. 
 
                                                        
2 Contact tracing is referred to the Tasmanian Sexual Health Service 
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1.13.3 What is the population under surveillance?   
The whole Tasmanian population. 
1.13.4 How is the data received and stored? 
The data is received on a daily basis following confirmation at the laboratory.  
Data is received either by fax or printer depending on the electronic set-up of the 
individual laboratory.  At times, data is received by mail.  The data is manually 
entered onto the Tasmanian Notifiable Diseases Database (TNDD) which is 
protected by password, and hard copy information is stored in locked filing 
cabinets in locked areas accessible only to authorised staff.  The TNDD is a 
Microsoft Access database.  The database allows easy extraction of data for 
statistical investigation and reporting. 
1.13.5 How is the data analysed? 
Data are extracted from the TNDD and epidemiology and surveillance staff 
within the CDPU conducts statistical investigations.  Quarterly trends are 
reported on the DHHS website (2) and to the Tasmanian Sexual Health Service to 
assist with their planning, quality assurance processes, contact tracing and 
research.  Data analysis also takes place within CDPU due to adhoc requests for 
data for research purposes and to inform and evaluate DHHS prevention 
activities.   
1.13.6 How is the information disseminated? 
Laboratory data is transferred electronically on a daily basis directly to the 
Communicable Disease Network of Australia (CDNA) through the National 
Notifiable Diseases Surveillance System (NNDSS). The data transferred does not 
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include any identifying information (such as surname and first name initials and 
suburb or postcode of residence).  CDNA analyses and reports on the data at a 
national level (3, 4).   
Hard copy case questionnaires are sent to the treating doctors of all cases for 
collection of additional data and to ascertain the need for assistance with contact 
tracing.  Data is provided electronically to the Tasmanian Sexual Health Service 
to assist with their planning, quality assurance processes, contact tracing and 
research.   
Deidentified data is also provided to ethics approved researchers on request.  
The CDPU provides summary data for dissemination to the general Tasmanian 
public through inclusion on the website of DHHS (2). 
The notification process is presented in Figure 1.5 
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Figure 1.5: Flow chart of the notification process 
Infection with Chlamydia trachomatis  
 
Presentation to medical practitioner, health clinic 
or hospital for testing 
Submission of sample for laboratory testing 
Positive laboratory evidence of Chlamydia 
trachomatis infection 
Notification sent by laboratory to the 
Communicable Diseases Prevention Unit, 
Department of Health and Human Services 
CDPU checks database for prior diagnosis within 
four weeks2 and notifications are then entered 
onto the Tasmanian Notifiable Diseases 
Database 
Questionnaire sent to treating doctor 
for collection of additional data Data electronically sent daily to the National Notifiable Diseases 
Surveillance System 
Data received from treating doctor 
and entered onto Tasmanian 
Notifiable Diseases database 
Reporting and analysis at State and 
National levels 
Control and prevention activities at 
State and National levels 
  31
 
1.13.7 Usefulness  
Information collected by the surveillance system contributes to the prevention 
and control of chlamydia by enabling active contact tracing through clinicians 
and the Tasmanian Sexual Health Service.  Contact tracing in turn leads to 
treatment.  The data collected is also used to drive policy of the Tasmanian 
Sexual Health Service including their clinical interventions and practices.   
The data collected is used to understand the notification trends and contributes 
to the measurement of public health strategies and policies surrounding the 
disease.  However, the system has limited ability to monitor, evaluate and inform 
public health policy and prevention activities and should be interpreted with 
caution.  The surveillance practices do not include collection of data on negative 
tests (people who were tested for chlamydia but tested negative) (testing data).  
This limitation can result in bias when planning and evaluating policies and 
prevention activities, as it does not allow for the impact of fluctuating patterns of 
testing coverage. 
1.13.8 Simplicity  
The Tasmanian Notifiable Diseases Database is simple to use and requires 
limited training to operate. The database is backed up at the end of each day by 
specialised IT staff.  When high volumes of data entry have been completed early 
in the day, an additional backup is usually conducted by CDPU staff and is a 
simple process.  The system of sending data on a daily basis electronically to the 
NNDSS is also simple to use.   
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Only laboratory confirmed notifications are received by CDPU, therefore it is not 
necessary to check case definitions or follow up laboratory tests to confirm each 
case.  Notifications are only received from laboratories, alleviating any problems 
associated with multiple levels of reporting.  Follow up with notifiers is rarely 
necessary and any changes, updates and follow-ups are relatively simple to 
implement. 
Receipt of notification faxes and letters is labour intensive and could be 
improved by the introduction of electronic notification systems.  This could also 
lead to a reduction in hard copy storage and handling for both the CDPU and the 
notifiers.  The system of data entry of each notified case is also highly labour 
intensive.  This could also be alleviated by the introduction of electronic 
notification systems. 
The system of sending out requests to treating clinicians to seek additional data 
is simple to operate, with letters and forms generated through a standard mail 
merge.  Return rates for enhanced data from clinicians is high, with little follow 
up necessary.  Due to the large volume of chlamydia notifications, the process of 
active follow up and additional data entry is labour intensive. 
Electronic transfer of data to NNDSS allows for easy analysis at a national level.  
State level analysis and reporting is simple through the extraction of data from 
the Microsoft Access database into statistical packages. 
1.13.9 Acceptability  
Surveys conducted with pathology laboratories in Tasmania on the reporting 
system have indicated a high level of acceptability.  As discussed above, the 
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introduction of electronic notification systems would increase the acceptability 
even further due to reduced labour intensive systems surrounding the sending of 
faxes and letters. 
The acceptability of the system by clinicians in Tasmania who provide the 
enhanced data is also high, with a return rate of requests for enhanced data of 
approximately 85% from 2001 to 2010 (5). 
CDPU staff who enter the data find the system simple to operate with easy 
accessibility to reporting and mail merge facilities.  Staff responsible for liaising 
with laboratories and treating clinicians find the system acceptable.  All staff 
reported concerns with the volume of notifications leading to the system being 
very high labour intensive. 
1.13.10 Sensitivity  
The surveillance system for chlamydia meets its objective of monitoring trends 
in notified cases, but is not able to detect outbreaks or determine the true 
frequency of the condition in the population.  The system cannot pick up every 
single case due to the large number of asymptomatic and untested cases that are 
estimated to be in the community. 
The laboratory testing methodologies for chlamydia are reliable, with high levels 
of sensitivity and specificity (6).  All cases entered onto the TNDD are laboratory-
confirmed and therefore sensitivity issues arising from misclassification of cases 
are unlikely. 
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The extent to which public health initiatives and increases in testing for 
chlamydia contribute to increases in notifications is unknown however the 
system is a useful and accurate measure of notification trends. 
1.13.11 Representativeness  
Notifications of chlamydia infection to the CDPU are predominantly received on 
young females between the ages of 16-25 years.  As chlamydia is equally sexually 
spread in males and females (7) this data suggests a significant under screening 
and underreporting in males.  Targeted testing of young women and higher rates 
of utilisation of health care (8) in this cohort may be fueling these higher 
notification rates. In Tasmania, Indigenous identifiers are incomplete in 
chlamydia surveillance data and therefore there are no reliable estimates of 
whether this population is represented. 
1.13.12 Timeliness  
The time lag between the onset of the condition and presentation by the case for 
testing at a doctor or clinic cannot be measured by the surveillance system.  The 
timeliness between specimen collection to information becoming available for 
public health action is acceptable and consistent with the objectives of the 
system.  A review undertaken in 2005 showed that the median number of days 
that it took from specimen collection to data entry at CDPU was 5 days. This 
timeframe included testing at the laboratory and notification by the laboratory to 
the CDPU. 
The review also found that the median time taken for the CDPU to send requests 
to clinicians for enhanced data was one day.  The median time it took for the 
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enhanced data to be received back from the clinicians was 8 days (D Coleman, 
Senior Surveillance Officer, DHHS, personal communication).   
1.13.13 Resources  
Prior to data entry of the chlamydia notification, a check of the database is 
undertaken to ensure a notification for the same person has not been received in 
the prior four weeks, and this quality assurance process increases the data entry 
time. The age of cases is also considered prior to data entry and any questionable 
cases are brought to the attention of the senior surveillance officer for 
confirmation and follow-up where necessary.  
Data is entered in batches, and once entered a mail merge is conducted for 
collection of enhanced data including the production of a form letter.  A pre-paid 
envelope is also included when sending the enhanced data request to clinicians, 
which adds to the time it takes to send out the request, but is considered to 
increase their return rate.  The data entry of notifications of chlamydia infection 
is incorporated amongst all surveillance data entry and it is difficult to assess the 
amount of full time equivalent employee’s time taken.  It is estimated that each 
chlamydia notification takes approximately 10 minutes to manage, including 
data entry and sending of enhanced data requests. This time does not include 
any time spent on analysing or interpreting the data. 
Most contact tracing is conducted either by the patient’s clinician or through the 
Tasmanian Sexual Health Service’s three regional health centres.  Approximately 
1% of contact tracing is conducted by the CDPU and therefore requires very little 
resources. 
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1.13.14 Discussion 
Tasmania’s chlamydia surveillance system is simple to use however it would 
benefit from the introduction of electronic laboratory reporting to alleviate the 
labour intensive nature of the work under current practices.  
The surveillance system is able to assist with case management and treatment 
including contact tracing, due to the active system of follow up of all treating 
doctors.  This is also labour intensive. 
The system is able to monitor trends in notified cases, however is not able to 
monitor population trends in infection due to the large number of asymptomatic 
and untested cases that are estimated to be in the community. 
The surveillance system would be greatly improved if it were able to collect data 
on negative tests.  This would allow for general adjustments of testing practices 
when monitoring trends for evaluation of prevention activities and other public 
health measures. 
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2 Chapter 2 — Chlamydia trachomatis in Tasmania 2001-
2007: rising notification trends  
2.1 Preface 
Although chlamydia is a notifiable disease in all Australian states and territories, 
Tasmania is the only jurisdiction to systematically conduct follow-up of the 
treating doctor of all notified cases for the purpose of collecting additional 
surveillance data.  Smaller studies have shown that additional surveillance can 
provide valuable epidemiological information useful in focusing chlamydia 
control efforts and in defining the burden of chlamydia in the Australian 
community. 
In this study, we analyse the unique dataset collected on chlamydia infections in 
Tasmania and provide a statistical comparison of rates in population sub-groups 
observed over the time period January 2001 to December 2007. 
This chapter has been published in the Australia and New Zealand Journal of 
Public Health and has been reproduced here with the permission of the 
publishers.   
Data from this analysis have also been published in Sexual Health (Shaw K, 
Stephens N, Coleman D, O’Sullivan M 2009) and included in Appendix A. 
 
 
  40
2.2 Abstract 
2.2.1 Objectives 
To investigate trends in notification rates of Chlamydia trachomatis in Tasmania, 
Australia, by population sub-groups, from 1 January 2001 to 31 December 2007. 
2.2.2 Methods 
An enhanced surveillance dataset was used to supplement case notifications. 
Rates based on age group were analysed by sex, geographic region, indigenous 
status, sexual exposure, reason for testing and healthcare provider. 
2.2.3 Results 
In all age groups, the notification rate increased steeply.  The highest rates were 
seen in the ages 15-24 years; this age group represented 15% of the population 
but accounted for 74% of the chlamydial notifications. The increased rates in 
females aged 15-24 years and males 15-19 years in Tasmania were larger than 
the increases observed nationally. Rates were consistently higher in urban areas. 
Females were more likely to have been tested as a result of screening, and males 
were more likely to have been tested when presenting with symptoms or as a 
result of contact tracing. The majority of cases reported sexual exposure with 
opposite sex partners only. 
2.2.4 Conclusions 
This study highlights the increasing significance of chlamydial infection as a 
public health issue, the gender differences in health-seeking behaviour, and the 
discrepancies in testing patterns. These findings will assist with the design of 
health promotion programs. 
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2.3 Introduction 
Genital infections with Chlamydia trachomatis (chlamydia) are a major 
cause of disease and morbidity internationally, and a steady rise in rates has 
been recognised in the past two decades (1, 2). The World Health Organization 
(WHO) estimates that the global disease burden for treating chlamydia 
patients is $10 billion per year (3). 
In Australia, chlamydia is the most common sexually transmissible 
bacterial infection(4) and the rate of notifications has increased each year since 
surveillance of the condition commenced in 1991 (5, 6). Nationally, notification 
rates have been consistently highest in the age groups 15-19 years and 20-24 
years, and these two age groups have also experienced the steepest increases in 
notification rates over time. 
Between 2001 and 2007 in Australia, the notification rates in females 
aged 15-19 years rose from 568 to 1,348 cases per 100,000 population, and in 
females aged 20-24 years the notification rates rose from 667 to 1614 cases per 
100,000 population. In males aged 15-19 years, notifications rose from 149 cases 
per 100,000 population in 2001 to 387 cases per 100,000 population in 2007, 
and for males 20-24 years the rates increased from 375 to 991 cases per 100,000 
population (7).  The costs of chlamydia infection for the Australian healthcare 
system have been estimated to be between $90 million and $160 million per 
year (8). Chlamydia infection can lead to significant health complications, 
including pelvic inflammatory disease, endometritis and ectopic 
pregnancy in women, and epididymitis and reactive arthritis in men (2, 9-
11). Chlamydia can also result in infertility in both males and females (12-
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15). A large proportion of chlamydia infections are asymptomatic (1, 8) and as a 
result often remain undiagnosed, increasing the likelihood of health 
complications (9-11) and adding to the spread of infection (16). 
Screening has been recognised as a cost- effective method of reducing the 
prevalence of chlamydia (8, 17-19), and chlamydial infection meets the WHO 
criteria for a screening program (8, 20). The Australian Government’s 
National Sexually Transmissible Infection Strategy 2005-2008 (21) identified 
chlamydia as a priority and as a result the Australian Government plans to 
implement systematic screening and testing in the general population. Who to 
screen, how often, in what setting, and type of screening program are all 
questions still under debate (19, 22-24). Although chlamydia is a notifiable 
disease in all Australian States and Territories, Tasmania is the only jurisdiction to 
conduct follow-up on all notified cases for the purpose of collecting enhanced 
data. Smaller studies have shown that enhanced surveillance can provide 
valuable epidemiological information useful in focusing chlamydia control efforts 
(8, 25) and in defining the burden of chlamydia in the Australian community (6).  
Since 2005, enhanced STI surveillance data has been collected nationally for 
gonococcal infection, donovanosis and syphilis (26), and the enhanced data 
collected on chlamydia in Tasmania is fully compatible with the data collected 
nationally for those infections. 
Our study analyses the unique dataset collected on chlamydia infections in 
Tasmania and provides a statistical comparison of rates in population sub-
groups observed over the time period January 2001 to December 2007. 
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2.3.1 Methods 
2.3.1.1 Case definition 
For the purposes of this study, a case was defined as a person with sexually 
acquired, laboratory conf irmed Chlamydia trachomatis (chlamydia) infection 
with specimen collection date from 1 January 2001 to 31 December 2007 
inclusive. Cases with ocular infections were excluded. Cases with a laboratory 
confirmed test for chlamydia within the previous four weeks were also excluded. 
Laboratory evidence was defined in accordance with the Communicable Diseases 
Network of Australia guidelines (27) as: 
• isolation of C. trachomatis from cell culture; 
• detection of C. trachomatis by nucleic acid testing; or 
• detection of C. trachomatis antigen. 
2.3.1.2 Data collection and management 
We identified our cases from the Tasmanian Notifiable Diseases Database (TNDD) 
held within the Communicable Diseases Prevention Unit (CDPU) in the 
Department of Health and Human Services (DHHS), Tasmania. Laboratories are 
obliged under the Public Health Act Tasmania 1997 to provide core data on all 
laboratory-confirmed cases of chlamydia to the CDPU (29) and treating 
clinicians were actively followed up by the CDPU for collection of the Tasmania-
specific enhanced data by a standard one-page mailed questionnaire (Table 2.1). 
All notified laboratory data was entered into the TNDD in preparation for 
reporting to the Commonwealth Department of Health and Ageing, and the 
Tasmanian enhanced data collected from clinicians was entered into a 
separate area of the TNDD created for the NNDSS STI surveillance dataset (26). 
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Data collected before 2005 was retrospectively coded and entered into the 
enhanced dataset. 
 
Table 2.1: Data collected on Chlamydia trachomatis infection in Tasmania 
Data Notified by Laboratories Data Collected from Clinicians 
Disease code Confirmation of case’s sex 
Laboratory name Indigenous status 
Laboratory number Reason for testing the patient – 
symptomatic or asymptomatic 
Specimen collection date If asymptomatic, reason for testing 
Surname – first two initials only Whether case reports sexual contact 
with: 
a/ person(s) of the opposite sex 
b/ person(s) of the same sex 
c/ person(s) of both sexes 
d/ unknown 
First name – first two initials only Past history of chlamydial infection, if 
yes, year(s) of previous infection(s) 
Date of birth Whether assistance with contact 
tracing is required 
Sex Whether case reports undertaking 
commercial sex work within the last 
twelve months 
Region of residence in Tasmania Any further comments 
Name of treating clinician  
Site of infection  
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2.3.1.3 Analysis 
Rates of notifications based on age group were analysed by sex, geographic 
region, indigenous status, sexual exposure, reason for testing and healthcare 
provider. Healthcare provider data was coded by one of the authors (DC), 
using pathology laboratory reports, the data collected on clinical facility type, and 
an up-to-date database of clinicians held within the TNDD (28). The geographical 
classification system was based on the Australian Standard Geographical 
Classification system (Australian Bureau of Statistics) (30). For analyses, cases 
classified as rural or regional were categorised as non-urban cases, and cases 
classified as metropolitan were categorised as urban cases. 
Population denominators were derived from the estimated resident 
population of each collection district obtained from the Australian Bureau of 
Statistics by sex and five-year age groups for each year of data collection (2001-
2007). Seven age groups were used for the analyses: 10-14 years, 15-19 years, 20-
24 years, 25-29 years, 30-34 years, 35-39 years and 40+ years. 
Data were extracted into a Microsoft
® 
Excel spreadsheet and analysed using 
Stata
® version 10.0 (Stata Corporation, College Station, TX, US) (Stata). 
Exposures were expressed as dichotomous variables and crude rate ratios 
(RR) with 95% confidence intervals (CI) were calculated. 
2.3.2 Results 
2.3.2.1 Incidence 
Between 1 January 2001 and 31 December 2007 inclusive, there were 5,072 
cases of chlamydia notified in Tasmania of which 99.6% (n=5,053) were isolated 
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by nucleic acid testing with the remainder (0.4%) detected by antigen testing. 
The number of notifications increased steeply each year from 2001 to 2007 in 
both males and females. 
The 1,116 notifications received in 2007 represented an increase of 202% over 
the number of reported cases in 2001 (n=369). Female notifications accounted 
for 67% of all cases (Figure 2.1). Enhanced data was collected for 85% of notified 
cases (n=4,301) with a response rate consistent with the core notification data 
set by both gender and age group. 
The median age of female cases was 20 years (range 13 to 61 years) and the 
median age of male cases was 23 years (range 14 to 69 years). In cases aged less 
than 30 years, female notifications greatly exceeded male notifications. Eighty 
per cent of female cases (n=2,717) were aged between 15 and 24 years. This 
age group of female cases made up 54% of the total of all notifications received 
over the study time period. Sixty-two per cent of male cases were aged between 
15 and 24 years (n=1,041). 
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Figure 2.1: Chlamydia notifications, Tasmania, 2001-2007 by sex 
 
2.3.2.2 Notification rates by age groups 
In all age groups, the notification rate per 100,000 population increased steeply 
over the period 2001 to 2007. In age groups under 35 years, in both sexes, the 
increases were significant. 
The highest rates for both sexes were seen in the age groups 15-19 years and 
20-24 years. Between 2001 and 2007, persons aged 15-24 years represented 
15% of the Tasmanian population (30), this same age group accounted for 
74% of the Tasmanian chlamydial notifications. 
Between 2001 and 2007, the notification rate for females in the 15-19 year age 
group increased by 1,127 cases per 100,000 population (195%, p<0.01), and the 
rate in females aged 20-24 years increased by 1,086 per 100,000 population 
(167%, p<0.01). In males, increases of 287 per 100,000 population (15-19 year age 
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group) (228%, p<0.01) and 472 per 100,000 population (20-24 year age group) 
(126%, p<0.01) were observed. 
2.3.2.3 Notification rates by urban/non-urban status 
The rate of chlamydia notifications per 100,000 population was consistently 
higher in urban areas than in non-urban areas. The rates for males and females 
in both geographic categories increased steeply over the seven-year period 
2001 to 2007. Urban rates increased by 213 cases per 100,000 population for 
females and by 109 cases per 100,000 population for males; and non-urban rates 
increased by 239 cases per 100,000 population for females and 107 cases per 
100,000 population for males (Figure 2.2). 
 
 
Figure 2.2: Rates of chlamydia notifications per 100,000 population, by 
urban status and sex, Tasmania, 2001-2007 
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2.3.2.4 Indigenous status 
Data on indigenous status was collected for 71% (n=1196) of male cases and 
68% (n=2319) of female cases. Two per cent reported Aboriginal or Torres Strait 
Islander origin. Notification patterns were found to be the same as in the general 
population. 
2.3.2.5 Commercial sex work 
Data on whether the case reported undertaking commercial sex work within the 
12 months prior to infection with chlamydia was received for 532 (32%) of 
notified male cases and 1077 (32%) of notified female cases. One male case and 
nine female cases were reported as having undertaken commercial sex work 
during that time period. 
2.3.2.6 Reason for testing 
Females were more likely to have been tested for chlamydia infection as a 
result of screening, and males were more likely to have been tested for 
chlamydia when presenting with symptoms or as a result of contact tracing 
(Table 2.2). 
Table 2.2: Reason for testing by sex, Chlamydia trachomatis notifications 
Tasmania 2001-2007 
Reason for testing Females (n=2894) Males (n=1408) 
Symptomatic presentation 1081 (37%) 737 (52%) 
Contact tracing 376 (13%) 455 (32%) 
Screening 1437 (50%) 216 (15%) 
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2.3.2.7 Sexual exposure 
The majority of cases reported sexual exposure with opposite sex partners only. 
Cases aged 35 years and older were more likely to report sexual exposure 
with same sex partners and less likely to report opposite sex partners than the 
younger age groups (Table 2.3). 
 
Table 2.3: Sexual exposure by age group, Chlamydia trachomatis 
notifications Tasmania 2001-2007 
Sexual 
exposure 
10-14 
yrs 
(n=23) 
15-19 
yrs 
(n=962) 
20-24 yrs 
(n=1105) 
25-29 
yrs 
(n=390) 
30-34 
yrs 
(n=141) 
35-
39yrs 
(n=75) 
40+ 
yrs 
(n=73) 
Opposite 
sex only  
22 
(96%) 
929 
(97%) 
1064 
(96%) 
363 
(93%) 
133 
(94%) 
64 
(85%) 
62 
(85%) 
Same sex 
only  
0 (0%) 30 (3%) 40 (4%) 24 (6%) 8 (6%) 10 
(13%) 
8 
(11%) 
Both 
sexes  
1 (4%) 3 (0%) 1 (0%) 3 (1%) 0 (0%) 1 (1%) 3 (4%) 
 
2.3.2.8 Healthcare provider 
Most cases were diagnosed by a general practitioner, however females were 
significantly more likely than males to be diagnosed through a public hospital (RR 
1.2; 95% CI 1.1-1.3) or a family planning clinic (RR 1.4; 95% CI 1.3-1.4), and 
less likely than males to be diagnosed through a general practitioner (RR 0.8; 
95% CI 0.8-0.8) or sexual health clinic (RR 0.7; 95% CI 0.7-0.8) (Table2. 4). 
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Table 2.4: Type of healthcare provider by sex, Chlamydia trachomatis 
notifications Tasmania 2001-2007 
Type of healthcare provider Females, n (%) Males, n (%) 
General Practice 2425 (71%) 1399 (84%) 
Family Planning Clinic 409 (12%) 40 (2%) 
Sexual Health Clinic 197 (6%) 192 (11%) 
Public hospital 156 (5%) 35 (2%) 
Private hospital 3 (0%) 4 (0%) 
Private obstetricians/gynaecologists 212 (6%) 0 (0%) 
 
2.3.3 Discussion 
Our study is the first in Australia to provide a comparison of chlamydia 
notification rates by subgroups derived from a population-based enhanced 
dataset collected over a seven-year period, with a valid high response rate. 
We found the majority of notifications were in people aged 15-24 years, with 
an over-representation of females in this age group. This peak can be interpreted 
in a number of ways including, greater utilisation of healthcare by females of this 
age, targeted and opportunistic testing within the cohort, and a cohort with 
high susceptibility to infection. Our results highlight the need for targeting safer 
sex interventions for this age group. 
As chlamydia is equally transmitted in males and females (6), our data suggests 
both significant under-screening and under-reporting in males. Strategies to 
improve screening in men need to be developed and continues to be an area in 
need of further research. Unlike females, males do not routinely consult a doctor 
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about their sexual health and contraception (31) unless symptomatic or alerted 
through partner notification systems. Awareness within general practice and 
emergency departments (32) of opportunistic screening of males who present 
acutely for other reasons would help boost screening, particularly given the ease 
of screening based on urine sampling. In general, however, males, particularly 
healthy young males in the age groups at most risk, access healthcare infrequently. 
The Australian Institute of Health and Welfare has found that males visit doctors 
consistently less than females (33), therefore it would be advantageous to 
consider extending screening into non-medical settings, such as sporting clubs, 
as proposed by Gold et al (34). 
Notification rates in males were highest in the cohort of 20-24 year olds and may 
be illustrative of the concept of age bridging (35).  Age bridging in this context is 
when a male has a female sexual partner who is two or more years younger.  
Jennings et al (35) found that this group of males often had multiple partners 
within short timeframes and were likely to use drugs and alcohol in relation to 
sexual intercourse. The available enhanced data from Tasmania does not confirm 
this behaviour but suggests a further area of research. 
The 2009 Guidelines for preventive activities in general practice from the Royal 
Australian College of General Practitioners (RACGP) suggests that all sexually 
active females aged under 25 years, and all sexually active people aged 15-25 
years with a recent change in sexual partner or with a pattern of inconsistent or 
no condom usage, should be screened for chlamydial infection every 12 months 
(36). Concentration on the under 25 year old females is reinforced by the 
Tasmanian dataset. 
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The increase in notification rates in Tasmania in females in the age groups 15-
19 years and 20-24 years and in males in the age group 15-19 years were larger 
than the increases that have been observed nationally (7). This would suggest 
that systematic screening in Tasmania should encompass people in the age range 
15-24 years, however jurisdictional differences may necessitate States and 
Territories establish tailored screening programs based not only on notification 
rates but also on rigorous modelling of potential strategies. 
The finding that older cases were more likely to report sexual exposure with 
same sex partners may reflect a real difference across age groups, or a 
reluctance of younger cases to disclose their sexual history to their treating 
medical practitioner. If disclosure is an issue, this has implications for effective 
contact tracing. Patient referral is used for almost all contact tracing (37), and 
patient reluctance has been found previously to be the most common barrier 
to contact tracing for sexually transmitted infections (38). 
Although the majority of cases had their infection diagnosed through a general 
practitioner, the range and the differences between the sexes and across age 
groups in choice of healthcare provider highlights the importance of the 
availability of a variety of services. This is particularly relevant to ensure that 
type of healthcare provider does not become an obstacle to testing for young 
people at highest risk of infection (39). 
Of note from our data is the small number of notifications that have come 
from hospitals. Chlamydia is associated with adverse pregnancy outcomes such 
as risk of pre-term delivery and premature rupture of the membranes (40) and 
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puerperal infections (41).  The RACGP suggests chlamydial screening be 
considered for pregnant women who are considered to be at increased risk 
(42). Chen et al’s (43) recent study supports this recommendation. They found 
that 72% of the infections detected in their study would have been found if 
screening had been restricted to all women under 20 years of age and all women 
aged 16-25 years who reported more than one sexual partner in the previous 12 
months. While some of the general practice notification figures may represent 
antenatal screening, the lack of hospital-based notifications highlights the need 
to consider routine chlamydia screening in hospital-based antenatal settings, 
particularly in the cohorts aged 15-24 years and those reporting more than one 
sexual partner. 
We detected consistently lower notification rates of infection in non-urban 
areas, a pattern observed elsewhere (2).  Our finding warrants further 
investigation, as it is not known whether it reflects inequitable access to chlamydia 
testing, a difference in health- seeking behaviours, or a true difference by 
geography. 
The type and sensitivity of diagnostic tests was constant over the study time period 
and, therefore, was unlikely to have influenced the increase in notification rates. 
Increased notifications could, however, be related to increased testing (17) and 
an exploration of the testing effort over the time period of the study is needed 
to assess this association. 
Excluding cases with a confirmed test within the previous four weeks point 
minimised the risk of including retests. Hosnefeld et al (44) conducted a 
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systematic review of the literature that examined reinfection with chlamydia and 
gonorrhoea and found that, in all but two of the studies included, reinfection 
was defined as a positive test greater than two weeks after an initial positive. In 
Australia, the Reinfection Period Convention Project conducted in New South 
Wales, developed conventions for reinfection periods based on best available 
evidence. The project found that 30 days after primary infection with chlamydia 
was the appropriate time period for subsequent positive diagnoses to be 
considered new episodes of infection (45). 
A limitation of our study is that enhanced data was not collected for 15% of cases. 
However, there was no difference found in the age, sex or geographical location 
of the cases for whom we collected enhanced data and for whom we did not, and 
therefore the risk of selection bias is minimal. 
The majority of notifications reported in our study were based on tests 
conducted as a result of symptomatic presentation or screening and as a large 
proportion of chlamydial infections remain asymptomatic, it is likely that our 
notification rates are an underestimation of the true rates. A formal 
epidemiological population-based prevalence study in Tasmania would allow a 
more accurate assessment of the rates and provide further evidence to inform 
planning of appropriate health services. 
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3 Chapter 3 — Improving public health surveillance of 
chlamydia: analysis of population-level positivity trends  
3.1 Preface 
The previous chapter examined the trends in notification data by population 
sub-groups.  In this chapter, we compare the chlamydia notification trends from 
2001 to 2010 to laboratory testing data from the same time period, to:  examine 
the usefulness of reporting positivity trends; determine whether observed 
increases in notifications were an artefact of testing practices; and improve 
understanding of testing practices of healthcare providers. 
This chapter has been published as a short report in Sexual Health and has been 
reproduced as an attachment to this chapter with the permission of the 
publishers. 
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3.2 Abstract 
3.2.1 Background 
Chlamydia remains Australia’s most frequently notified communicable disease, 
however interpretation of notification data is difficult without knowledge of 
testing practices. This study aimed to examine the usefulness of reporting 
positivity trends; determine whether observed increases in notifications were an 
artefact of testing practices; and improve understanding of testing practices of 
healthcare providers. 
3.2.2 Methods 
We compared Tasmanian chlamydia laboratory tests and notification data from 
2001 to 2010.  Notifications were analysed by age group, sex, healthcare 
provider and region; and tests were analysed by positivity, age group, sex, region 
and laboratory.  
3.2.3 Results 
Notification rates increased in males (381%) and females (410%); with highest 
rates in males and females aged 15-24 years.  Test numbers increased in males 
(277%) and females (168%), with largest increases in the age groups between 
15-29 years (males 338%, females 180%). Positivity increased in males (114%) 
and females (50%) with the most significant increases in males and females aged 
15-19 years (150%, 94%) and 20-24 years (94%, 83%).  Test positivity was 
highest, and number of tests lowest, in the northwest region. General 
practitioners notified 75% of cases. Private laboratories conducted 72% of tests.   
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3.2.4 Conclusions 
Analysis of population-level chlamydia positivity improved our interpretation of 
trends in the notification data. After allowing for testing effort, we found a 
significant increase in chlamydia infections in young people.  Reporting positivity 
trends is a more useful method of surveillance than reporting trends in notified 
cases. We recommend health authorities report positivity trends whenever 
possible, to improve the ability to develop, monitor and evaluate prevention and 
control activities.   
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3.3 Introduction 
Chlamydia trachomatis (chlamydia) is associated with significant short and long-
term morbidity, including adverse reproductive outcomes and increased 
transmission of other sexually transmissible infections; and the burden of 
disease related to chlamydia infections impacts heavily on health services (1).  
Chlamydia is Australia’s most frequently notified communicable disease; 
notifications have been increasing steeply since it first became notifiable in 1991, 
and the highest notification rates are in young people aged between 15 and 29 
years (2).  In Tasmania, increases in notification rates in these age groups have 
been reported as greater than those observed nationally (3).  
To enable planning of public health priorities and to inform policy to reduce the 
incidence of chlamydia, Australia’s National Sexually Transmissible Infections 
Strategy (NSTIS) highlights the importance of understanding the chlamydia 
epidemic through analysis of surveillance data (4). It is difficult, however, to 
interpret the epidemiology of chlamydia from surveillance data alone (5-7).  
Surveillance data reported to health departments does not include negative test 
results and denominator data is essential to be able to understand whether 
fluctuations in rates of notifications reflect testing practices (5, 7, 8). Analysis of 
both positive and negative tests can more accurately describe trends, improve 
interpretation of the epidemiology, and therefore improve the ability to plan, 
monitor and evaluate prevention and control programs (5, 8).  
Analysis and reporting of laboratory testing data is being used increasingly as a 
surveillance tool both internationally and within Australia.  In England, the 
Chlamydia Testing Activity Dataset (CTAD) collects chlamydia data from all 
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National Health Service (NHS) and NHS-commissioned laboratories. The purpose 
of CTAD is to monitor population screening coverage, and the trends in the 
proportion of positive tests. England’s priority is to reduce the incidence of 
chlamydia, and measuring the proportion of the target population tested each 
year is a crucial component of its program (9, 10).  In the United States, the 
Centers for Disease Control and Prevention (CDC) reports test trends in its 
annual Sexually Transmitted Disease Surveillance reports to assist in monitoring 
the burden of the disease and guide screening programs (11). Norway 
implemented a laboratory based surveillance system in 2005 whereby they 
collect the total number of chlamydia tests performed and the number of 
diagnosed cases once a year from all laboratories, and in 2007 improved their 
system to collect additional information on age, gender and geography in order 
to better interpret trends (12).  In New Zealand, chlamydia is not notifiable and 
measurement of trends in laboratory tests and positivity is used for surveillance 
purposes (13). 
In Australia, the proportion of chlamydia tests positive (positivity) has been 
reported in a number of studies and reviews (14-17) and sentinel surveillance 
systems have contributed importantly to the surveillance of chlamydia by 
collecting and analysing testing and positivity trends (5, 6, 18).  The Australian 
Collaboration for Chlamydia Enhanced Sentinel Surveillance (ACCESS) group and 
others recommend the ongoing monitoring of positivity to better understand 
trends in chlamydia notifications (5, 11, 12).  
Although general practitioners (GPs) notify the majority of chlamydia cases (3) 
and the Royal Australian College of General Practitioners recommends annual 
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screening of all sexually active young people aged less than 15-29 years 
(particularly those: aged under 20 years, of Aboriginal or Torres Strait Islander 
origin, who report inconsistent or no condom usage, or a recent change in sexual 
partner) (19); low chlamydia testing rates in young people who attend GP 
practices have been reported (20).  The NSTIS has prioritised support for GPs to 
promote opportunistic sexual health checks (4), and the level of testing for 
chlamydia in GP practices in Tasmania needs investigation (20). 
The aims of this study were to:  
• Examine the usefulness of collecting population-level chlamydia testing 
data as a surveillance tool;  
• Compare Tasmanian population chlamydia positivity trends with the 
notification data from 2001 to 2010, to determine whether the steep rise 
in notifications reflected a true increase in infections, or whether the rise 
was an artefact of testing practices; and 
• Improve understanding of chlamydia testing practices of Tasmanian 
health care providers. 
3.3.1 Methods 
We identified our cases from the Tasmanian Notifiable Diseases Database 
(TNDD) held within the Communicable Diseases Prevention Unit (CDPU) in the 
Department of Health and Human Services (DHHS), Tasmania.  Laboratories are 
required under the Public Health Act Tasmania 1997 to notify all laboratory-
confirmed cases of chlamydia to the DHHS (21).  A case in our study was defined 
as a person aged 10 years and over with chlamydia infection detected by nucleic 
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acid testing or direct immunofluorescence, between 1 January 2001 and 31 
December 2010.  Cases notified with ocular infections or with a laboratory 
confirmed test for the same disease within the previous four weeks were 
excluded.  Notifications were analysed by age group, sex, geographical region of 
residence (south, north, north-west)(22) and healthcare provider.     
Extensive discussions were held with all pathology laboratories in Tasmania to 
highlight the importance of collecting denominator data in order to improve 
understanding of the trends in chlamydia notifications. The researchers 
acknowledged the sensitivities associated with the commercial interests of the 
laboratories, and it was agreed by all parties that laboratory data would be 
combined by the researchers, and that the testing conducted by individual 
laboratories would not be reported or shared with any other party.  Laboratories 
agreed to provide the age, sex, postcode of residence and result of test for all 
chlamydia tests generated by Tasmanian-based clinicians from 2001 to 2010.  
Where indicated, post treatment tests conducted within the same month were 
excluded. Testing data were analysed by: result of test, age groups, sex, 
geographical region of case residence, and type of laboratory (private or public). 
Positivity was calculated by dividing the total number of positive tests by the 
total number of tests conducted. 
This research was undertaken in accordance with Tasmania’s Personal 
Information Protection Act 2004 (23), in particular Schedule 1 of the Personal 
Information Protection Principles contained within the Act.  In addition, the 
release of the de-identified dataset was authorised by the Director of Public 
Health under the provisions of the Public Health Act 1997 (21). Laboratories de-
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identify laboratory reports prior to notifying DHHS of confirmed cases of 
chlamydia.  Only the first two initials of the first and last name (2x2 name codes) 
of cases of chlamydia are notified, with addresses removed and inclusion of only 
the postcode of residence.  De-identified data fields relevant to this analysis were 
extracted from the TNDD by author 2 for the purposes of this analysis.  
Laboratory testing data did not include 2x2 name codes.  
All data were extracted into Microsoft Excel spreadsheets and analysed using 
Stata version 12.0 (Stata Corporation, College Station, TX, US) (Stata). We 
conducted chi-squared tests to analyse testing and positivity trends, and linear 
regression to analyse notification trends. 
3.3.2 Results 
3.3.2.1 Notifications 
Chlamydia notifications increased steadily over the 10-year study period, with 
10,024 cases notified in total. Female cases made up 66% (n=6603) of 
notifications. Eighty-eight percent (n=8,828) of notified cases were aged 
between 15 and 29 years.  The median age of male cases was 22 years (range 14 
to 82 years, IQR 21-24 years); the median age of female cases was 20 years 
(range 12-63 years; IQR 18-24 years). 
General Practitioners notified 75% (yearly range 72-77%) of cases (82% of male, 
71% of female) and 97% of the GP notified cases were diagnosed in private 
laboratories. In males, sexual health clinics notified 13% of cases, public and 
private hospitals and family planning clinics combined notified less than 6%.  
Family planning clinics notified 11% of female cases, sexual health clinics 7%, 
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public hospitals and other clinics 5% each, and private hospitals <1% of female 
cases.  Notifiers, other than GPs, utilised public health laboratories for 78% of 
their testing. 
In males, the notification rate increased from 66 to 318 cases per 100,000; in 
females, the notification rate increased from 115 to 586 cases per 100000 (both 
Ptrend<0.001). Notification rates were highest in females aged 15 to 19 years, 
followed by females aged 20 to 24 years, and males aged 20 to 24 years (Figures 
3.1 and 3.2). 
 
Figure 3.1: Chlamydia notification rates in males, by age group, Tasmania 
2001 to 2010  
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Figure 3.2: Chlamydia notification rates in females, by age group, Tasmania 
2001 to 2010  
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2010. Test numbers increased significantly over time in both males (278%) and 
females (168%), and greatest in those aged 15 to 29 years (males 338%, females 
180%) (all Ptrend <0.001) (Figure 3.3).  
 
Figure 3.3: Total number of chlamydia tests by year and sex, and number of 
tests in those aged 15 to 29 years by year and sex, Tasmania, 2001 to 2010 
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Table 3.1: Chlamydia test positivity, Tasmania 2001 to 2010, by sex, age 
group, region, and laboratory type 
  Proportion of tests positive 
  2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
Males                     
 15-19 years* 8.0 14.0 12.7 12.8 14.4 19.2 19.4 20.7 19.9 20.7 
 20-24 years* 9.0 15.1 19.0 15.0 21.9 19.3 18.8 19.8 17.8 18.7 
 25-29 years 6.0 9.9 10.5 13.4 13.7 10.8 13.0 13.1 8.9 12.6 
 30-34 years 2.0 11.3 7.7 7.8 9.6 8.5 6.6 8.0 7.8 7.7 
 35-39 years 1.4 5.1 4.9 8.2 8.6 4.1 2.3 5.0 6.1 6.8 
 40+ years 2.6 1.7 3.3 2.3 2.2 2.5 2.7 3.6 1.3 3.2 
Females                     
15-19 years* 8.0 10.1 9.8 10.6 12.7 10.7 12.8 14.1 13.1 15.5 
 20-24 years* 5.3 8.0 8.5 9.2 8.4 8.8 8.4 9.5 7.9 9.7 
 25-29 years 4.9 3.4 3.7 4.2 4.7 4.8 5.6 3.6 5.0 5.0 
 30-34 years 3.3 2.3 2.2 1.4 3.4 2.3 2.8 2.5 2.4 3.4 
 35-39 years 3.8 1.5 0.9 0.8 1.9 3.3 0.2 1.8 1.4 2.3 
 40+ years 0.6 0.7 1.0 1.1 0.6 1.0 0.9 1.3 0.8 1.1 
REGION                     
  South* 7.6 6.8 6.8 6.8 7.1 7.0 7.4 8.6 7.6 8.9 
  North* 3.6 6.0 7.3 7.6 8.2 7.2 6.9 8.5 7.4 8.8 
  North-west* 4.1 6.3 7.1 7.9 9.0 9.5 9.7 9.8 9.2 10.7 
Laboratory                     
  Private* 5.9 6.6 7.3 7.5 8.0 7.7 8.1 9.0 8.2 9.6 
  Public* 4.6 5.7 6.1 6.3 7.7 6.9 6.6 8.4 6.9 8.1 
Note: 10-14 years removed from table due to small numbers, * Ptrend<0.001 
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3.3.2.4 Regions 
When compared to the proportion of the Tasmanian population residing in each 
region, notifications and testing proportions were higher in the south and north 
than in the north-west (Table 3.2).  Positivity was highest in the north-west 
(Table 3.1).  
Table 3.2: Proportion of Tasmanian population, chlamydia notifications 
and chlamydia testing, by region 
Region  
% of 
Tasmanian 
population 
% of 
notifications 
% of 
testing 
South 50 51 52 
North 28 29 31 
North-west 22 20 17 
 
3.3.2.5 Laboratories 
Private laboratories conducted 72% of the testing (yearly range 67% to 76%).  
Test positivity was higher in private laboratories, and increased significantly in 
both private and public laboratories (Table 3.1).  
3.3.3 Discussion 
Analysis of trends in positivity improved our interpretation of trends in the 
notification data.  Our study was the first in Australia to measure chlamydia 
positivity at a population level over a 10-year period and compare the results to 
notifications.  We found a significant increase in chlamydia infections in males 
and females aged between 15 and 24 years, and to a lesser extent in males and 
females aged 25 to 29 years.  These increases remained after allowing for testing 
effort, inferring the prevalence of chlamydia has increased. Increases in 
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positivity were found in all regions of Tasmania.  Higher positivity and lower 
testing rates were found in the northwest region, possibly as a result of reduced 
access to testing. Lower chlamydia testing rates (24) and higher chlamydia 
positivity (5, 14) have been observed in regional and rural areas in Australia, and 
access to chlamydia testing has been found to favour more advantaged areas 
(25).  Young people are noted as a priority population, and barriers to accessing 
sexual health services for young rural people is a focus, of the NSTIS (4) 
Our results are supported by the findings of sentinel surveillance.  The ACCESS 
group found a significant increase in positivity in both males and females aged 
15 to 29 years from 2006 to 2010, and in multivariate analysis found younger 
age to be independently correlated with positivity (males 15-19 years, adjusted 
odds ratio (AOR) 1.22; males 20-24 years AOR 1.32; females 15-19 years AOR 
1.71; females 20-24 years AOR 1.58) (5).  The Victorian Primary Care Network 
for Sentinel Surveillance found an increase in chlamydia positivity in both males 
and females, significant in females and highest in women aged 16 to 19 years 
(18).  Targeted Australian studies have also found increases in chlamydia 
positivity over time, after adjusting for changes in clinical presentation, sexual 
behavior and demographics in both men (16) and women (17).   
Large increases in testing were observed over the 10 years, with the greatest 
increases in males, particularly young males, indicating the gender gap in testing 
practices is narrowing. We were unable to adjust our testing for variations in the 
population being screened, such as symptom status or sexual exposure and 
therefore could not determine any changes in the characteristics of the males 
being tested.   
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General practitioners (GPs) play a crucial role in the identification of chlamydia 
infection in the Australian population regardless of age, sex or geographic 
location of the patient (26).  GPs notified the majority of cases in our study, and it 
is likely that the large increase in testing observed in our study was primarily a 
result of an increase in testing by GPs.  We were unable to analyse our testing 
data by healthcare provider; however, as our analysis of testing data found that 
most of the testing was conducted in private laboratories, and as our notification 
data showed that GPs made up a large proportion of users of the private 
laboratory system, we believe the notification data can be extrapolated to the 
testing data.  We acknowledge the contribution GPs are making to the testing of 
young people for chlamydia, and recommend that GPs continue to work towards 
achieving optimal testing rates by addressing barriers to testing such as time 
pressures, lack of knowledge (27), and concerns about discussing sexual health 
(20).  We reiterate the priority of the NSTIS to increase support of GP screening 
initiatives (4), and recommend provision of funding to assist GPs to screen 
patients more comprehensively (26). 
The number of notified cases and the number of positive tests were very similar, 
with 7% more positive tests reported over the 10 years than notified cases.  The 
difference might be explained by inclusion of repeat tests or ocular infections in 
the testing data, or under-reporting in the notification data. This limitation was 
consistent across all years of the study and should not have an effect on the 
observed trends, strengthening our assertion that the trends observed in the 
testing data can be extrapolated to the notified cases.  
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Ongoing data collection and reporting of population-level positivity could be 
improved by the inclusion of both a unique identifier for patients and the type of 
healthcare provider ordering the test.   
A range of commercial nucleic acid tests with minor variations in lower limits of 
detection, were used in laboratories throughout the period of the study.  This 
may have had a small influence on the positivity rate.  Exclusion of second, post 
treatment, specimens collected within the same month is likely to reduce the 
impact of variation in detection rates.  Similarly local and temporal changes in 
specimen type may also have impacted the detection rates (L. Cooley, Head of 
Microbiology, Royal Hobart Hospital, Tasmania, personal communication, 2014). 
The greatest strength of our study was its coverage of the whole population 
tested for chlamydia in Tasmania. Lewis et al (2012) (15) point out in their 
comprehensive review that as chlamydia testing rates continue to increase in 
Australia, surveillance data will be able to provide a more reliable estimate of the 
prevalence of chlamydia in the population.  In the meantime, costs of ongoing 
studies to monitor chlamydia prevalence at a population level are prohibitive, 
and sentinel surveillance is only able to provide data on targeted populations (5, 
18).  Surveillance data, generally, is limited by low testing rates, asymptomatic 
infection, and other characteristics that prevent people from either presenting to 
health practitioners to be tested for infection, or by health practitioners choosing 
not to test. Despite this, we have demonstrated that analysis of laboratory testing 
data is useful for surveillance purposes, to allow for general adjustment of 
testing practices and, importantly, to enable reporting of trends for public health 
purposes.  Monitoring trends in population-level positivity is sustainable and 
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cost-effective, and could be included routinely in public health surveillance and 
reporting. We were able to add a considerable amount of epidemiological 
knowledge by measuring chlamydia positivity trends at a whole-state level.  
Reporting on positivity is an improved method of chlamydia surveillance and we 
recommend that health departments seek population-level chlamydia testing 
data as a surveillance tool, whenever possible.  This will enable health 
authorities to enhance their surveillance reports, which will in turn improve the 
ability of policy makers and public health practitioners to develop, monitor and 
evaluate chlamydia prevention and control activities.  It will also directly address 
one of the key priorities of the NSTIS, being: to improve methods of measuring 
testing coverage for STIs (4). 
3.3.3.1 Postscript 
This chapter measured chlamydia test positivity at a population level, based on 
all tests conducted in the population.  Tests were deidentified.  Chapters 5, 6 and 
7 examine population-level testing based on individuals, and assess the impact of 
geographic location and socio-economic status on the testing and positivity 
trends. 
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4 Chapter 4 — Exploration of testing practices and 
population characteristics support an increase in 
chlamydia positivity in Tasmania between 2001 and 
2010 
4.1 Preface 
In the previous chapter, we compared chlamydia notification data with 
laboratory testing data and demonstrated that after allowing for testing effort an 
increase in chlamydia infections in young people was observed. 
In this chapter, we explore whether the symptom status, reason for testing, or 
sexual exposure of notified cases could explain the observed positivity trends. 
This chapter has been published in the Australia and New Zealand Journal of 
Public Health and has been reproduced here with the permission of the 
publishers. 
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4.2 Abstract    
4.2.1 Objective 
The proportion of positive chlamydia tests in young people in Tasmania 
increased significantly between 2001 and 2010. Whilst female positivity rates 
increased steadily, male positivity rose steeply to 2005 then stabilised. Crude 
positivity rates can be influenced by a variety of factors making interpretation 
difficult.  Unique Tasmanian datasets were used to explore whether symptom 
status, reason for testing or sexual exposure could explain the observed 
positivity trends.  
4.2.2 Methods 
Population-level chlamydia positivity rates in Tasmania over a ten-year period 
were compared with surveillance data collected on people aged 15 to 29 years 
notified with chlamydia.  
4.2.3 Results 
The proportion of asymptomatic chlamydia cases increased, with the largest 
increase in males aged 15 to 19 years (28%).  Opportunistic testing of  cases 
increased (greatest in males, range 17-32%).  Sexual exposure remained 
consistent.  
4.2.4 Conclusions 
After allowing for any changes in sexual exposure, symptom status, and reason 
for testing, an increase in chlamydia positivity occurred over the 10 years. 
Healthcare providers have increased chlamydia testing in high risk groups.  
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4.2.5 Implications 
Monitoring chlamydia testing patterns and positivity rates at a population level 
is a major step forward in surveillance practices.  Targeted surveys provide 
valuable information to supplement routine surveillance data. 
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4.3 Introduction 
Chlamydia trachomatis (chlamydia) is Australia’s most frequently notified 
communicable disease (1).  Young people are disproportionately affected, with 
over 80 per cent of notifications occurring in males and females aged less than 
30 years (1, 2).  Untreated infections are associated with an increased risk of 
pelvic inflammatory disease, ectopic pregnancy and infertility (3, 4), and the 
morbidity associated with chlamydia impacts significantly on health service 
costs (5-7).   
Effective diagnosis and treatment of people infected with chlamydia is the key to 
controlling the spread of infection (8).  Targeted testing of priority populations is 
essential. Under the Australian Government’s Third National Sexually 
Transmissible Infections Strategy (National STI Strategy), sexually active young 
people aged under 30 years are an important priority population due to their 
high notification rates (2).  Mathematical modelling indicates that adequate 
levels of testing for chlamydia infection can result in a significant reduction in 
prevalence (8, 9).  Specifically, Regan et al (2008) found that if 40% of people 
aged less than 25 years in Australia were tested annually, chlamydia prevalence 
would reduce dramatically over a 10 year period, with over 50% of the reduction 
occurring within the first four years (8).  Similar optimal testing coverage rates 
have been suggested in modelling studies conducted in the Netherlands, where it 
was reported that a 30% testing coverage would have a substantial impact (9).   
The National STI Strategy (2) stresses the importance of ongoing support and 
training of healthcare providers to address any issues and barriers to testing of 
at risk populations; including how to raise an STI-testing opportunity in a non-
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sexual-health consultation. It has been reported that as many as three quarters 
of chlamydia cases can be missed if STI-testing is limited to only those who 
display genital symptoms or report a partner with an STI (10). As chlamydia is 
mostly asymptomatic (3, 11, 12), regular testing of all sexually active young 
people, not just those who present with symptoms, is a vital component of 
strategies to increase testing efforts (2).  General practitioners (GPs) are the 
main providers of sexual health services in Australia and play a crucial role in the 
identification of chlamydia infection in the population regardless of age, sex or 
geographic location of the patient (2, 13-15).  However, a survey of GPs (16) and 
results from the Australian Collaboration for Chlamydia Enhanced Sentinel 
Surveillance (17), show that GPs are more likely to test patients who report 
symptoms of chlamydia or a recent risk event (contact tracing).  
Notification rates can reflect testing practices (18) and caution is needed when 
interpreting chlamydia notification trends without knowledge of the tested 
denominator (19).  To help overcome this limitation, we previously reviewed all 
chlamydia tests conducted in Tasmania from 2001 to 2010  (20). Tasmania is an 
island state of Australia with a population of about 510,000.  People aged 15 to 
29 years accounted for around 19% of the population across all years of our 
study. Our analysis found a significant increase in both testing rates and the 
proportion of positive chlamydia tests (chlamydia positivity).  The largest 
increases in testing were in males aged 15 to 19 years, in whom testing 
increased 475% over the 10 years, followed by males aged 20 to 24 years and 
males aged 25 to 29 years.  The greatest increases in positivity were in males and 
females in the age groups 15 to 19 years and 20 to 24 years, and males aged 25 
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to 29 years.  We found that chlamydia positivity in young males rose steeply 
from 2001 to 2005, after which time it stabilised to 2010.  Female chlamydia 
positivity rose more steadily from 2001 to 2010 (20).  
Characteristics of the tested population and risk behaviours can impact on crude 
positivity rates (21) and in this paper we assess these influences on the observed 
chlamydia positivity trends in Tasmania.  For the first time in Australia we were 
able to perform these analyses at a population level, focusing on symptom status, 
reason for testing, and sexual exposure of people aged 15 to 29 years notified 
with chlamydia from 2001 to 2010 and comparing the results with the positivity 
trends. 
4.3.1 Methods 
4.3.1.1 Data sources and study population 
Our study population included all people aged 15 to 29 years living in Tasmania 
between 2001 and 2010 with a laboratory confirmed Chlamydia trachomatis 
(chlamydia) infection (22) notified to the Department of Health and Human 
Services (DHHS), Tasmania.  People with a laboratory confirmed positive test 
with a collection date within the previous four weeks were excluded as part of 
routine surveillance practices. Laboratories are required under the Public Health 
Act Tasmania 1997 to notify all laboratory-confirmed cases of chlamydia to the 
DHHS (23). Data collected from mandated laboratory notifications include the 
specimen collection date, first two letters of the case’s given name and first two 
letters of the case’s surname (name coded), date of birth, sex and postcode of 
residence (24).  Additional data on sexual exposure, symptom status and reason 
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for testing were collected from the diagnosing clinician of each case by a 
standard one-page mailed questionnaire (14). Clinicians were asked: 1/ whether 
the case reported sexual exposure with person(s) of the opposite sex only; 
person(s) of the same sex only; person(s) of both sexes; or unknown sexual 
exposure; 2/ whether the case was symptomatic or asymptomatic; and 3/ if 
asymptomatic, whether the case was tested opportunistically or as a result of 
contact tracing.   
Extensive discussions were held with all pathology laboratories in Tasmania to 
highlight the importance of collecting denominator data in order to improve 
interpretation of the chlamydia notification trends.  It was agreed that laboratory 
data would be combined by the researchers, and that the testing conducted by 
individual laboratories would not be reported.  Laboratories provided the age, 
sex, postcode of residence and result of test for all chlamydia tests generated by 
Tasmanian-based clinicians from 2001 to 2010.  No identifying information was 
collected.   
4.3.1.2 Statistical Analyses 
Case notifications were analysed by year, age group (15-19 years, 20-24 years, 
25-29 years), sex, sexual exposure, symptom status and reason for testing. 
Testing data were analysed by year, result of test, age group and sex.  Positivity 
was calculated by dividing the total number of positive tests by the total number 
of tests conducted.  The overall crude testing rate was calculated by dividing the 
total number of tests conducted in males and females aged 15 to 29 years, by the 
total population in that age group in Tasmania over the 10-year study period.  
Annual crude testing rates were calculated by dividing the number of tests 
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conducted in males and females by the total male and female populations, 
separately, by year and age group.  Population denominators were derived from 
the estimated resident population obtained from the Australian Bureau of 
Statistics (25).  All data were extracted into Microsoft Excel spreadsheets and 
analysed using Stata version 13.1 (Stata Corporation, College Station, TX, US) 
(Stata).  We conducted chi-squared tests to analyse testing and positivity trends, 
and linear regression to analyse notification trends. 
4.3.1.3 Ethics 
This research was undertaken in accordance with Tasmania’s Personal 
Information Protection Act 2004 (26), in particular Schedule 1 of the Personal 
Information Protection Principles contained within the Act.  In addition, the 
release of the dataset was authorised by the Director of Public Health under the 
provisions of the Public Health Act 1997 (23). De-identified data fields relevant to 
this analysis were extracted from the DHHS database by author 2 for the 
purposes of this analysis (24).  
4.3.2 Results 
4.3.2.1 Notifications 
There were 8,828 chlamydia infections notified by laboratories in people aged 
15 to 29 years over the 10-year study period. Females accounted for 68% 
(n=6,004) and males 32% (n=2,824). Additional surveillance data was collected 
for >85% (n=7,536) of cases.  The age and sex distributions of cases with 
additional surveillance data were consistent with the age and sex distributions of 
all notified cases.   
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Notification rates increased significantly between 2001 and 2010 in both males 
and females (both Ptrend<0.01).  In 2010, notification rates were highest in 
females aged 15 to 19 years (3,698 per 100,000), followed by females aged 20 to 
24 years (2,815 per 100,000), males aged 20 to 24 years (1,638 per 100,000), 
males aged 15 to 19 years (1,096 per 100,000), females aged 25 to 29 years (917 
per 100,000) and males aged 25 to 29 (750 per 100,000). 
4.3.2.2 Sexual exposure 
Data on sexual exposure was reported in 88% (n=1,916) of male and 87% 
(n=4,122) of female notified cases between 2003 and 2010. The pattern of 
reported sexual exposure was consistent over the study period in both males 
and females. Ninety four percent of males (n=1,801) and 96% of females 
(n=3,957) reported sexual exposure with opposite sex only.  More males than 
females reported same sex exposure (9% of 25-29 year old males vs 4% of 25-29 
year old females; 5% 20-24 year old males vs 3% 20-24 year old females; 4% 15-
19 year old males vs 3% 15-19 year old females).   
4.3.2.3 Symptom status of notified cases   
Data on symptom status was collected from 2001 to 2010, and was reported for 
85% of males (n=2,389) and 86% of females (n=5,147) notified with chlamydia.  
Fifty-six percent (n=1,330) of males and 65% (n=3,370) of females were 
asymptomatic when tested.  The proportion of males who were asymptomatic 
when tested increased by 15% between 2001 and 2010. The steepest increase 
was in males aged 15 to 19 years (28%). The proportion of females who were 
asymptomatic when tested increased by 6% (Table 4.1).   In males, there was a 
sustained crossover in 2005 in the symptom status proportions (Figure 4.1).  In 
  98
females, the asymptomatic proportion remained consistently higher than the 
symptomatic proportion each year with the exception of one year (Figure 2). 
Forty four percent of male cases (n=1,059) and 35% of female cases (n=1,777) 
were tested after presenting to their treating clinician with symptoms (Table 
4.1). 
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Table 4.1: Notified chlamydia cases by symptom status, and reason for 
testing asymptomatic cases; and, total number of chlamydia tests 
conducted and test positivity rates, by age group and sex, Tasmania 2001 
to 2010 
    Proportions (%) 
    2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
Symptom status – all notified cases 
Males                       
15-19yrs Symptomatic 65 59 43 54 39 49 32 38 39 37 
  Asymptomatic 35 41 57 56 61 51 68 62 61 63 
20-24yrs Symptomatic 50 57 57 58 50 42 42 44 42 40 
  Asymptomatic 50 43 43 42 50 58 58 56 58 60 
25-29yrs Symptomatic 58 67 63 61 50 47 41 34 42 50 
  Asymptomatic 42 33 37 39 50 53 59 66 58 50 
Females                       
15-19yrs Symptomatic 43 48 35 39 42 36 37 30 35 34 
  Asymptomatic 57 52 65 61 58 64 63 70 65 66 
20-24yrs Symptomatic 39 51 33 36 36 30 30 29 31 32 
  Asymptomatic 61 49 67 64 64 70 70 71 69 68 
25-29yrs Symptomatic 33 61 34 43 31 36 34 24 37 31 
  Asymptomatic 67 39 66 57 69 64 66 76 69 69  
Reason for testing - asymptomatic notified cases 
Males                       
15-19yrs   Contact tracing 86 78 69 92 79 83 60 48 52 63 
    Opportunistic 14 22 31 8 21 17 40 53 48 37 
20-24yrs   Contact tracing 71 68 74 73 82 74 62 56 51 54 
    Opportunistic 29 32 26 27 18 26 38 44 49 46 
25-29yrs   Contact tracing 75 78 69 73 61 63 54 49 51 43 
    Opportunistic 25 22 31 27 39 38 46 51 49 57 
Females                       
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    Proportions (%) 
    2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 
15-19yrs   Contact tracing 28 21 26 25 14 15 17 21 26 16 
    Opportunistic 72 79 74 75 86 85 83 79 74 84 
20-24yrs   Contact tracing 20 21 17 16 21 14 29 24 19 19 
    Opportunistic 80 79 83 84 79 86 71 76 81 81 
25-29yrs   Contact tracing 31 56 20 21 30 24 15 19 38 16 
    Opportunistic 69 44 80 79 70 76 85 81 63 84 
Number of tests conducted and positivity (proportion of tests positive)  
Males                       
15-19yrs No. of tests 159 179 228 273 299 375 463 647 759 914 
 Positivity 8 14 13 13 14 19 19 21 20 21 
20-24yrs No. of tests  351 444 542 618 635 800 896 1152 1311 1453 
 Positivity 9 15 19 15 22 19 19 20 18 19 
25-29yrs No. of tests 251 333 389 382 454 557 610 807 821 939 
 Positivity 6 10 11 13 14 11 13 13 9 13 
Females                       
15-19yrs No. of tests 1397 1441 1729 1825 2119 2709 2626 2931 3322 4188 
 Positivity 8 10 10 11 13 11 13 14 13 15 
20-24yrs No. of tests 1863 2068 2169 2293 2934 3703 3468 3682 4197 5001 
 Positivity 5 8 8 9 8 9 8 9 8 10 
25-29yrs No. of tests 1071 1096 1132 1282 1556 1967 2052 2115 2517 2894 
 Positivity 5 3 4 4 5 5 6 4 5 5 
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Figure 4.1: Symptom status at time of testing notified cases of chlamydia, 
and proportion of all chlamydia tests conducted that were positive, in 
males aged 15 to 29 years, Tasmania from 2001 to 2010 
 
 
Figure 4.2: Symptom status at time of testing notified cases of chlamydia, 
and proportion of all chlamydia tests conducted that were positive, in 
females aged 15 to 29 years, Tasmania, from 2001 to 2010 
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4.3.2.4 Reason for testing – asymptomatic cases 
Data on reason for testing was collected from 2001 to 2010, in 85% of males 
(n=2,389) and 86% of females (n=5,147) notified with chlamydia. Of the 1,330 
asymptomatic male cases, 61% (n=805) were tested as a result of contact 
tracing, with the remaining 39% (n=525) tested opportunistically.  The 
proportion tested opportunistically increased over time.  The largest increases 
were observed in males aged 25 to 29 years in whom opportunistic tests 
increased by 32% from 2001 to 2010, followed by males aged 15 to 19 years 
(23% increase), and males aged 20 to 24 years (17% increase).  Of the 3,370 
asymptomatic female cases, 21% (n=692) were tested as a result of contact 
tracing and 79% (n=2,678) were tested opportunistically. Smaller increases in 
the proportion of female cases tested opportunistically were observed, with the 
largest increase seen in the oldest age group (13% in 15-19 years; 1% in 20-24 
years; 15% in 25-29 years) (Table 4.1). 
4.3.2.5 Testing and positivity  
There were 91,972 chlamydia tests conducted in people aged 15 to 29 years 
from 2001 to 2010, equating to an overall crude testing rate of 10%.  Crude 
annual testing rates increased from 2% to 7% in males and from 10% to 26% in 
females, from 2001 to 2010.  Tests with indeterminate results (0.5%) and in 
whom sex was not reported (0.2%) were excluded, leaving 91,388 tests in our 
analysis.  Twenty percent (n=18,041) of tests were in males and 80% (n=73,347) 
were in females. Sixteen per cent (n=2,908) of male tests and 9% (n=6,519) of 
female tests were positive for chlamydia. The median age of males tested was 22 
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years and of females tested was 21 years.  Of those with a positive result, the 
median age of males was 21 years and median age of females was 20 years.   
In all males, positivity increased from 8% in 2001 to 17% in 2010 (Figure 4.1). 
Positivity in males aged 15 to 19 years increased steeply from 8% in 2001 to 
19% in 2006, at which time it stabilised, fluctuating between 19% and 21% from 
2006 to 2010 (p<0.001).  In males aged 20 to 24 years, positivity increased from 
9% in 2001 to a peak of 22% in 2005, before stabilising with a range of 18% to 
20% from 2006 to 2010 (p<0.001).  Positivity in males aged 25 to 29 years 
increased from 6% in 2001 to a peak of 14% in 2005, and fluctuated to 2010 
(p=0.01). In all females, positivity increased from 6% in 2001 to 11% in 2010 
(Figure 4.2). In females aged 15 to 24 years, increases in positivity were less 
steep than males and more consistent over the 10 years. In females aged 15 to 19 
years, positivity increased from 8% in 2001 to 15% in 2010 (p<0.001), and in 20 
to 24 year old females, positivity increased from 5% in 2001 to 10% in 2010 
(p<0.001).  The positivity rate fluctuated in females aged 25 to 29 years with a 
smaller increase over the 10 years, 4.9% to 5.0% (p=0.04) (Table 4.1). 
4.3.3 Discussion 
Adequate levels of testing for chlamydia in sexually active young people, both 
symptomatic and asymptomatic, is a key public health goal, fundamental to the 
success of strategies to control the chlamydia epidemic in Australia (2, 27). 
Despite recent increases in the rate of chlamydia testing in some populations, 
further improvements in testing of people from at risk groups and methods to 
monitor testing coverage, are critical (2, 28).   
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Current Australian health department surveillance, and sentinel targeted 
surveillance activities, are unable to monitor population-level testing practices, 
nor determine the characteristics of the whole population being tested.  For the 
first time in Australia, we are able to report 10-year chlamydia positivity trends, 
and assess the symptom status, reason for testing, and sexual exposure of people 
being tested for chlamydia, at a population level.  Pleasing increases in chlamydia 
testing in Tasmania in young people generally (20), and, importantly, increased 
testing of asymptomatic young people aged 15 to 29 years were found. This 
suggests that healthcare providers (HCPs) are striving to reach the goals set by 
the National STI Strategy (2).  
Males have consistently been underrepresented in chlamydia notification data, 
despite the infection being equally transmitted in males and females (29), and 
asymptomatic males are also less likely than asymptomatic females to be tested 
for chlamydia (30).  Yeung et al (2014) found that both males and females are 
likely to agree to chlamydia testing if asked, regardless of symptom status (10).  
In our study, although females still made up the greatest proportion of notified 
cases, we found that HCPs increased their testing in males at a greater rate than 
in females (20), and, most notably, their testing of asymptomatic young males.  
Males aged between 15 and 29 years generally access healthcare infrequently 
and do not routinely consult a doctor about their sexual health (31) unless 
symptomatic or alerted through partner notification systems (contact tracing) 
(14).  In this study, we found increases in testing for chlamydia infection that 
occurred opportunistically.  These increases were again most notable in males.  
In the earlier years of our study, the proportion of asymptomatic young males 
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who were tested as a result of contact tracing was dominant; however that 
proportion changed over time, with the gap narrowing between those tested as a 
result of contact tracing and those tested opportunistically.   
We also explored the influence of sexual exposure on positivity trends.  Gay men 
and other men who have sex with men have a higher prevalence of STIs (2, 32) 
and an increase in testing in this population could impact trends in positivity. 
Our results show that sexual exposure remained consistent over the study 
period.   
In our interpretation of the data we have assumed that the pattern of testing 
observed in the notified cases (people who tested positive and were notified to 
the DHHS) is the same in people who tested negative for chlamydia.  We 
therefore assume that the proportion of asymptomatic people who were tested 
but were negative for chlamydia has increased at a similar rate to those who 
tested positive.  In other words, we conclude that HCPs are testing more 
asymptomatic young people, generally.  
Following this hypothesis, the pattern of symptom status in notified cases over 
the 10 years of our study can help explain the observed positivity trends.  The 
flattening of the positivity rate in males from 2005 through to 2010 occurred 
simultaneously with increases in the proportion of asymptomatic male cases 
notified to the DHHS.  We postulate that an increase in testing of asymptomatic 
young males overall (that is, a change in the population being tested) contributed 
to the flattening of the positivity rate, and that the flattening rate does not reflect 
a decrease in the prevalence of cases in the young male population. 
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Similar findings have been described by Vodstrcil et al (2011), who in their 
retrospective review of data held by the Melbourne Sexual Health Centre, found 
that chlamydia positivity in men who have sex with men (MSM) did not change 
significantly between 2002 and 2009, while at the same time the proportion of 
those presenting with symptoms decreased (p<0.01).  They argued that the 
flattening of the positivity rate in the MSM resulted from the high testing rates in 
that population (about half of MSM reported being tested each year) and the 
decrease in symptomatic presentation (33). 
The additional surveillance data we collected from clinicians as part of our study 
provided us with valuable information on the characteristics of notified cases.  
Good response rates were obtained for collection of data on all three 
characteristics of interest allowing us to better understand the trends in the 
passive routine surveillance data.  We found no demographic differences 
between the cases for whom we collected additional surveillance data and for 
whom we did not, suggesting the risk of selection bias was minimised.  However, 
as the additional surveillance data was collected from diagnosing clinicians 
rather than the notified cases themselves, the data was dependent on the 
accuracy of the clinicians’ responses. 
The greatest strength of our study was that it was based on the whole population 
in Tasmania.  There were several limitations.  We found that only 10% of the 
population in the study age group had been tested, equivalent to that reported 
previously in young Australian adults (10, 17).  This limitation may have 
decreased over the time of our study, as the number of tests conducted in young 
people increased, and as the proportion of asymptomatic people tested 
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increased.  The surveillance practice of excluding cases notified within 30 days of 
a previous positive result may have resulted in some testing data being included 
without a matching notified case.  Male testing rates and notifications were 
substantially lower than in females, and may have introduced biases to our 
analyses of both positivity trends and population characteristics.  Studies have 
demonstrated that the prevalence of chlamydia is similar in males and females 
(30); therefore, the higher positivity rate we found in males is likely to be a 
reflection of the lower testing rates and the higher proportion of symptomatic 
males tested (34), rather than higher male prevalence.  Further, our data is 
Tasmania-specific, and the generalisability of our findings to other geographical 
areas is unknown. 
The gold standard for reporting population level positivity would be to report on 
persons tested rather than tests conducted.  Our study was limited by the de-
identified nature of both the laboratory and notification data.  We were unable to 
ascertain whether a person was tested or notified more than once in each year.  
Repeat tests can inflate estimates of population testing coverage based on the 
number of tests (35), and surveillance data collected on notified cases could be 
biased by the inclusion of individuals more than once in any year.  Collecting 
unique identifiers and linking the laboratory testing data to allow for analysis of 
the data by persons would result in a considerable improvement. Under these 
circumstances, we could measure the proportion of 15-29 year olds receiving a 
chlamydia test annually, and the proportion that yield a positive result.  
Collection of individual identifiers would also allow for more sophisticated 
analyses.  Our study was able to demonstrate trends in notification and 
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laboratory testing data through descriptive analytical techniques. Future 
research based on individuals, rather than tests, would benefit from the use of 
multivariable regression analysis to explore the impact age, reason for testing, 
gender and symptom presentation have on chlamydia positivity.  
 
We conclude that after allowing for any changes in sexual exposure, symptom 
status, and reason for testing, an increase in chlamydia positivity occurred 
between 2001 and 2010 in males and females aged 15 to 29 years in Tasmania. 
Previous studies have suggested that positivity can be used as a proxy measure 
for prevalence (36, 37) in all healthcare settings, including general practice (36). 
We were unable to adjust for repeat tests, therefore our denominators may have 
been overestimated, resulting in an underestimation of prevalence (36, 37); and 
the lower testing rates in males may have further impacted on the estimation of 
chlamydia prevalence in males (36, 38).   Our results support the findings of 
others who have reported that the true prevalence of chlamydia is increasing in 
young people (33, 39).   
4.3.4 Implications 
We have demonstrated that it is possible to work closely with laboratories to 
establish a surveillance system that is able to monitor testing practices and 
chlamydia positivity at a population level.  Reporting trends in chlamydia 
positivity is a more useful method of surveillance than reporting trends in 
notified cases.  In the absence of data being available on individuals tested, 
health authorities responsible for chlamydia surveillance should strive to report 
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on crude chlamydia positivity at a population level, thereby providing critical 
evidence to inform best public health practice and policy that takes into account 
the influence of testing practices.  The collection of sex, date of birth, postcode 
and result of test for all chlamydia testing conducted in each jurisdiction is 
achievable and would be a major step forward in chlamydia surveillance in 
Australia. 
We have also shown the value of collecting additional surveillance data from 
diagnosing clinicians and the possibility of a high response rate.  Our data assists 
in filling an identified gap in knowledge of characteristics of notified cases of 
chlamydia at a population level (28, 31) and compliments the passive 
surveillance data collected by health authorities in Australia (21).  Collection of 
additional surveillance data at a population level can be resource intensive 
particularly for jurisdictions with large populations, but we argue that it is 
possible to tightly target data collection to key questions and obtain data that is 
crucial to both public health policy development and to increased understanding 
of positivity trends.  We recommend health authorities conduct periodic surveys 
of healthcare providers who are diagnosing and treating young patients with 
chlamydia, and that the surveys are kept to a maximum of five key questions 
including the symptom status and reason for testing their patients.  
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5 Chapter 5 — Testing for chlamydial infection: are we 
meeting clinical guidelines? Evidence from a state-level 
data linkage analysis for 15-29 year-olds 
5.1 Preface 
Clinical guidelines recommend annual Chlamydia trachomatis (chlamydia) tests 
for all sexually active people aged 15 to 29 years.  In this chapter, we report on 
our linkage of all chlamydia tests conducted in Tasmania in 2012 and 2013 in 
residents aged 15 to 29 years, to measure adherence to these guidelines and to 
compare testing rates to the projected levels required to reduce chlamydia 
prevalence. 
This paper has been submitted for publication to the Medical Journal of Australia 
and is currently under review. 
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5.2 Abstract 
5.2.1 Objective 
Clinical guidelines recommend annual Chlamydia trachomatis (chlamydia) tests 
for all sexually active people aged 15-29 years. This study measured adherence 
to these guidelines and compared current testing rates to the projected levels 
required to reduce chlamydia prevalence.  
5.2.2 Design, setting and participants 
We linked all chlamydia tests conducted in Tasmania during 2012-2013, in 
residents aged 15-29 years. Data linkage allowed individuals with multiple tests 
across different healthcare settings to be counted only once each year in testing 
rate analyses.   
5.2.3 Main outcome measures 
Rates of testing and test positivity by age, sex, test rebate status and 
socioeconomic indicators. 
5.2.4 Results  
There were 31,899 eligible tests in 24,830 individuals. Testing coverage was 
higher in females (21%, 19,404/92,685) than males (6%, 5,426/98,123), and 
highest in females 20-24 years (26%, 8,072/30,558). Positivity was higher in 
males (16%, 862/5,426) than females (10%, 1,854/19,404). Most tests (81%, 
25,803/31,899) were rebateable.  Positivity was higher in females with non-
rebateable tests (12%, 388/3,116 vs rebateable 9%, 1,466/16,285). Less testing 
(1.8%, 7,284/391,734) and higher positivity (11%, 822/7,284) were found in 
areas of most disadvantage compared to middle (1.9%, 9,688/510,754; 10%, 
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983/9,688) and least (2.0%, 1,680/85,894; 8%, 139/1,680) disadvantaged 
areas.  
5.2.5 Conclusions 
Chlamydia testing rates are lower than recommended levels.  Sustaining the 
current testing rates in females aged 20-24 years may reduce population 
prevalence over 10 years. Our study meets key priorities of national strategies 
for chlamydia control by providing a method of monitoring testing coverage and 
evidence to evaluate prevention programs.  Our methods could be applied in 
other geographical areas to monitor testing trends and inform targeted testing. 
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5.3 Introduction 
Chlamydia trachomatis (chlamydia) is Australia’s most frequently notified 
communicable disease and young people aged 15 to 29 years account for 80% of 
cases (1). Chlamydia is of public health significance because of the short- and 
long-term sequelae associated with untreated infection, including urethritis, 
acute epididymitis and infertility in males, and cervicitis, urethritis, pelvic 
inflammatory disease, infertility, chronic pelvic pain and tubal pregnancy in 
females (2).  Reducing the transmission of chlamydia is a priority under 
Australia’s Third National Sexually Transmissible Infections Strategy, and 
reduction is critically dependent on increasing testing coverage (1).  Chlamydia 
is asymptomatic in up to 80% of infected males and females, which makes it 
essential that all sexually active young people, not just those presenting with 
symptoms, be screened to detect the majority of cases and provide treatment (3).  
Mathematical modelling has demonstrated that large reductions in chlamydia 
prevalence are possible, provided there is adequate testing coverage in the 
target population (3). The Royal Australian College of General Practitioners (4) 
and the Australian STI Management Guidelines (5) recommend annual screening 
of all sexually active young people aged <30 years.  
Under public health legislation in Australia, laboratories (and doctors in some 
states) are required to report chlamydia diagnoses to their jurisdiction’s health 
department.  These reports routinely include the date of specimen collection or 
diagnosis date, and the diagnosed person’s sex, age and postcode of residence 
(6).  This enables national and local analysis of notifications by sex, age and 
geographic location (7, 8).  However, these chlamydia surveillance practices do 
  122
not include the collection of data on negative tests (people who were tested for 
chlamydia but tested negative) (testing data).  This limitation can result in bias 
when planning and evaluating policies and prevention activities as it does not 
allow for the impact of fluctuating patterns of testing coverage. Chlamydia 
testing data is also necessary to monitor progress against recommended clinical 
testing targets (1). Sentinel surveillance and studies in Australia have been able 
to partially address this knowledge gap by reporting on chlamydia testing 
coverage in selected populations (9-14), but are limited by the inclusion of 
restricted samples of laboratory data, treating healthcare practitioners or 
facilities.  
For the first time in Australia, we undertook data linkage of all chlamydia testing 
conducted by both public and private healthcare providers, in people aged 15-29 
years at a state-population level over a two-year period.  Our study design 
enabled us to include every test conducted in the population and to link 
individuals who may have been tested more than once, by more than one 
healthcare provider and in more than one laboratory.  This linkage enabled us to 
meet the primary research aims of our study, being: 1/ to assess adherence to 
clinical guidelines for chlamydia testing; 2/ to identify demographic and clinical 
setting differences; and 3/ compare the results to strategies to reduce chlamydia 
prevalence. 
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5.3.1 Methods 
5.3.1.1 Study population and laboratory testing data 
People aged 15 to 29 years resident in Tasmania (an island state of Australia of 
approximately 512,000 people). People in the study age group made up 19% of 
the state’s population in 2012 (n=95,837) and 18% in 2013 (n=94,988) (15).  
Results of every chlamydia test conducted from 1 January 2012 to 31 December 
2013 were collected from all public and private laboratories and made available 
to the Tasmanian Data Linkage Unit (TDLU) (16).  
5.3.1.2 Data linkage  
Data linkage was conducted at the TDLU through a process of ‘Probabilistic 
Linkage’ which involved linking the datasets using a combination of unique 
identifiers together with a base level of administrative variables including name, 
address, date of birth and sex with the requirement that records being compared 
agree on all characters. Unique patient identifiers were created and a de-
identified dataset made available to the authors for the purpose of analysis that 
included the variables: laboratory identifier, unique patient identifier, postcode 
of residence, date of birth and sex; date, and result of test; and Medicare rebate 
(a government payment for conducting a test) eligibility status (coded as 
rebateable or non-rebateable). 
5.3.1.3 Socioeconomic indicators 
Each person was assigned an Index of Relative Socioeconomic Disadvantage 
(IRSD) decile score as prescribed under the 2011 Socio-economic Indexes for 
Areas (SEIFA), based on their postcode of residence.  SEIFA is a product 
  124
developed by the Australian Bureau of Statistics that ranks areas in Australia 
according to their relative socio-economic advantage and disadvantage.  The 
population-based IRSD deciles represent groups of individuals who live in 
similarly ranked areas. IRSD scores range from 1 to 10, with 1 being the most 
disadvantaged relative to the other deciles (17). For analysis purposes, IRSD 
scores were categorised into three groups based on deciles 1 and 2 (most-
disadvantaged areas), 3 to 8 (middle-disadvantaged areas) to 9 and 10 (least-
disadvantaged areas).  Analysis was restricted to people tested at private 
laboratories.  Postcodes of people tested at public laboratories were unreliable 
due to an unknown proportion allocated the postcode of sexual health services, 
corrective services and youth centres. 
5.3.1.4 Estimates of the sexually active population  
Two data sources were utilised for estimating the sexually-active proportion of 
the population:  1/ the Second Australian Study of Health and Relationships that 
examined the age of first vaginal sex via a nationally representative sample of 
20,094 Australian residents aged 16 to 69 years in 2012 and 2013 (18); and 2/ 
the 2013 5th National Survey of Australian Secondary Students and Sexual 
Health which enrolled over 2,000 year 10, 11 and 12 students from across public 
and private school systems and examined the age at first intercourse (19). We 
defined sexually active as having ever had any type of sexual intercourse.   
5.3.1.5 Analysis  
We measured the number of tests conducted, test positivity, test rebate status 
and disadvantage score by age group (15 to 19; 20 to 24; 25 to 29 years) and sex; 
and the number of individuals tested and individual positivity, by age and sex. 
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Each person was counted once in a 12-month period, and repeat tests were 
removed.  In individuals with multiple tests and discrepant results, the positive 
test was retained.  
Population denominators were derived from the estimated resident population 
of each collection district obtained from the Australian Bureau of Statistics for 
2012 and 2013.  Chlamydia positivity rates were calculated by dividing the 
number of positive tests by the number of tests conducted. Equivocal tests (tests 
unable to be confirmed as positive or negative) were excluded.  
In the estimated sexually active population, the numbers of individuals tested 
were calculated by sex and single age between 15-20 years and by the age group 
21-29 years, based on census population denominators and in line with the 
available sexually active population estimates described above. 
Data were analysed using Stata version 14.1 (Stata Corporation, College Station, 
TX, US).  We conducted chi-squared tests to analyse testing and positivity trends 
and linear regression to assess testing and positivity by IRSD score.   
5.3.1.6 Ethical approval 
This study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee. 
5.3.2 Results   
5.3.2.1 Study population and laboratory testing data 
A total of 32,791 nucleic acid tests were conducted in 24,830 individuals; 74% 
were conducted in private laboratories; 180 (0.5%) were excluded due to 
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equivocal or missing results and 712 (2%) due to missing or interstate postcode. 
Females made up 79% (25,130/31,899) of tests included in the study.  
5.3.2.2 Rates of testing and positivity 
The highest rate of testing was conducted in females aged 20-24 years.  Across 
all age groups, tests in males were significantly lower than in females (p<0.001). 
The testing rate in males and females combined for the age range 15-29 years 
was 13%, and in the age range 15-24 years was 14% (Table 1). 
Test positivity was highest in males aged less than 20 years (Table 1). Males 
(p<0.01) and females (p<0.001) aged 25-29 years were significantly less likely to 
have a positive test than younger age groups (Table  5.1). 
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Table 5.1: Population rates of testing and test positivity, in males and females aged 15 to 29 years tested for chlamydial 
infection in Tasmania in 2012 and 2013 
  
No. of 
tests 
No. of 
positive 
tests 
Positivity 
No. of 
individuals 
tested* 
No. of 
individuals with 
a positive test** 
Individual 
positivity** 
Census population 
2012 & 2013 
Population 
testing rate 
Males                 
 15-19 years 1907 412 22% 1531 272 18% 35250 4% 
 20-24 years 3181 646 20% 2538 431 17% 32754 8% 
 25-29 years 1681 255 15% 1357 159 12% 30119 5% 
Total 6769 1313 19% 5426 862 16% 98123 6% 
Females 
        
 15-19 years 8656 1685 20% 6343 874 14% 32357 20% 
 20-24 years 10523 1482 14% 8072 751 9% 30558 26% 
 25-29 years 5951 424 7% 4989 229 5% 29770 17% 
Total 25130 3591 14% 19404 1854 10% 92685 21% 
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No. of 
tests 
No. of 
positive 
tests 
Positivity 
No. of 
individuals 
tested* 
No. of 
individuals with 
a positive test** 
Individual 
positivity** 
Census population 
2012 & 2013 
Population 
testing rate 
 Combined - males and females             
 15-19 years 10563 2097 20% 7874 1146 15% 67607 12% 
 20-24 years 13704 2128 16% 10610 1182 11% 63312 17% 
 25-29 years 7632 679 9% 6346 388 6% 59889 11% 
Total 31899 4904 15% 24830 2716 11% 190808 13% 
 Combined - males and females             
 15-24 years 24267 4225 17% 18484 2328 13% 130919 14% 
*individuals counted once in a 12 month period, **repeat tests removed, in individuals with discrepant results positive tests retained
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5.3.2.3 Sexually active population rates of testing and positivity  
The proportion of the population estimated to be sexually active ranged from 
14% (15-year-old females) to 96% (21-29 year-old males) (18,19).  Under these 
assumed estimates, the annual testing rate for sexually active people in the age 
range 15-29 years was 18%, and in the age range 15-24 years was 20% (Table 
5.2). 
Test positivity amongst the estimated sexually active population was highest in 
males aged 19 years (Table 5.2). 
5.3.2.4 Socioeconomic indicators 
Less testing (1.8%, 7,284/391,734) occurred in areas of most disadvantage, 
compared to testing in middle  (1.9%, 9,688/510,754) and least disadvantaged 
(2.0%, 1,680/85,894) areas (p=0.01).  People living in most disadvantaged areas 
were more likely to have a positive result (11%, 822/7,284) than people living in 
middle (10%, 983/9,688) and least (8%, 139/1,680) disadvantaged areas 
(p=0.01) (Table 5.3). 
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Table 5.2: Proportion of the estimated sexually activea,b males and females aged 15 to 29 years tested for chlamydia in 
Tasmania in 2012 and 2013 
  
No. of 
individuals 
tested* 
No. of 
individuals with 
a positive test 
Individual 
positivity 
Census 
population 
2012 & 2013 
Population 
testing rate 
Estimated sexually active 
proportion of population 
Testing rate 
in sexually 
active  
Males           % No.   
 15 years 89 8 9% 6853 1% 18a-22%b 1234-1508 6%-7% 
 16 years 200 29 15% 7021 3% 34a-36%b 2387-2528 8% 
 17 years 334 48 14% 7176 5% 52%a,b 3732 9% 
 18 years 439 88 20% 7205 6% 67%a 4827 9% 
 19 years 469 99 21% 6995 7% 75%a 5246 9% 
 20 years 535 102 19% 6768 8% 81%a 5482 10% 
 21-29 years 3360 488 15% 56105 6% 96%a 53861 6% 
Females                 
 15 years 540 60 11% 6423 8% 14a-23%b 899-1477 37%-60% 
 16 years 890 137 15% 6584 14% 32a-34%b 2107-2239 40%-42% 
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No. of 
individuals 
tested* 
No. of 
individuals with 
a positive test 
Individual 
positivity 
Census 
population 
2012 & 2013 
Population 
testing rate 
Estimated sexually active 
proportion of population 
Testing rate 
in sexually 
active  
 17 years 1415 182 13% 6622 21% 49%a,b 3245 44% 
 18 years 1717 263 15% 6464 27% 65%a 4202 41% 
 19 years 1781 232 13% 6264 28% 74%a 4635 38% 
 20 years 1700 210 12% 6195 27% 80%a 4956 34% 
 21-29 years 11361 770 7% 54133 21% 95%a 51426 22% 
acalculated from the Second Australian Study of Health and Relationships21; bcalculated from the 5th National Survey of Australian Secondary Students and Sexual Health22; *individuals counted once in a 12 month 
period; **repeat tests removed, and in individuals with discrepant results, positive tests retained 
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Table 5.3: Chlamydia tests and positivity, by IRSD score^, males and 
females aged 15 to 29 years tested in private laboratories, Tasmania 2012 
and 2013 
  
Most disadvantaged 
areas* 
Middle disadvantage 
areas** 
Least disadvantaged 
areas*** 
No. 
tested  
No. 
positive Positivity 
No. 
tested 
No. 
positive Positivity 
No. 
tested 
No. 
positive Positivity 
  
                  
Males                   
 15-19 
years 498 95 19% 569 109 18% 82 11 13% 
 20-24 
years 624 123 20% 996 186 17% 221 23 10% 
 25-29 
years 431 48 11% 471 72 13% 119 10 8% 
Females                    
 15-19 
years 1812 273 15% 2190 257 12% 301 27 9% 
 20-24 
years 2274 201 9% 3110 273 9% 601 49 8% 
 25-29 
years 1645 82 5% 2352 86 4% 356 19 5% 
Combined 7284 822 11% 9688 983 10% 1680 139 8% 
^IRSD scores range from 1 to 10, with 1 being the most disadvantaged relative to the other deciles. For analysis purposes, IRSD 
decile scores were divided into three groups, ranging from 1 and 2 (most-disadvantaged areas), 3 to 8 (middle-disadvantaged 
areas) to 9 and 10 (least-disadvantaged areas). *Population 195867; ** Population 255377; ***Population 4294
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5.3.2.5 Test rebate status 
Most tests were eligible for a rebate (81%, 25,803/31,899).  The likelihood of a 
test being eligible for a rebate increased as age increased in both males 
(p<0.001) and females (p<0.001).  In males, no difference was found in test 
positivity between those with rebateable and those with non-rebateable tests.  
The likelihood of a positive test was higher in females with non-rebateable tests 
(females aged 15-19 years, non-rebateable 16%, 202/1,266; rebateable 13%, 
672/5,077) (p=0.06), (females aged 20-24 years, non-rebateable 11%, 
153/1,433; rebateable 9%, 598/6,638)  (p<0.001) (females aged 25-29 years, 
non-rebateable 8%, 33/147; rebateable 4%, 196/4,570) (p<0.01). 
5.3.3 Discussion 
5.3.3.1 Adherence to clinical guidelines 
Despite clinical guidelines recommending annual chlamydia tests for all sexually 
active people aged 15 to 29 years, we found an annual testing rate of only 13% in 
this age group.  The testing rate was still low (18%) when assuming the 
estimated sexually active proportion.  Our testing rates were, however, higher 
than those previously reported in young people attending general practice in 
Australia (<10%) and considerably higher than those reported in Tasmania 
(2.4%) in 2007-2008 (10), reflecting an increase in testing rates over the last 
decade (20).   
5.3.3.2 Demographic and clinical differences 
Less testing occurred in areas of most disadvantage, but people living in areas of 
most disadvantage were more likely to have a chlamydia infection diagnosed.  
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Disadvantage has been similarly reported in New South Wales, where increasing 
socioeconomic disadvantage was associated with an increased notification risk 
(11), and in Victoria, where disadvantaged members of the community received 
significantly less chlamydia testing but had a greater likelihood of testing 
positive (12).  Lack of access to services has previously been cited as leading to 
less testing in areas of most disadvantage (12, 21); and people living in areas of 
most disadvantage are also less likely to submit a specimen and to be tested for 
chlamydial infection when requested by a general practitioner (GP) (21). 
The large majority of tests in our study were rebateable, and most rebateable 
tests are conducted by private healthcare providers, highlighting their important 
role in the diagnosis and management of chlamydia infections in Australia.   
5.3.3.3 Comparison to strategic targets for reduction of prevalence 
Mathematical modelling shows that the overall testing coverage (rather than 
whether tests are conducted in males or females) is the key to reducing 
chlamydia prevalence, and that if 40% of people aged <25 years were tested 
annually there would be a rapid decrease in prevalence in all age groups over a 
10-year period, with >50% occurring in the first 4 years (3).  Our testing rate in 
15-24 year olds (14%) was well below the required testing rate.  Our proportion 
tested (20%) was more encouraging when assuming the estimated sexually 
active population. 
Targeted testing of 20-24 year olds has a greater (~2-fold) impact on prevalence 
than testing 15-19 year olds or 25-29 year olds (3).  Pleasingly, our testing rates 
were highest in the age group 20-24 years, in both males and females.  Our 
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testing rates of 23% in females aged <25 years and 21% in females aged <30 
years were particularly promising when compared to the projected rates 
required to reduce prevalence within 10 years (estimated at 30% in females 
aged <25 years and 20-30% in females aged <30 years) (3).  In the estimated 
sexually active population, our testing rates of 35% in females aged <25 years 
and 30% in females aged <30 years both exceeded the projected targets.  A 
sustained testing effort in females in this age range should impact positively on 
prevalence rates. 
5.3.3.4 Strengths and limitations 
To the best of our knowledge, this is the first study in Australia to conduct an 
assessment of adherence to clinical guidelines for chlamydia testing at a state-
population level, and our report provides valuable evidence to guide clinical 
practice.  The linkage of the results of all chlamydia tests enabled us to include 
every individual tested for chlamydia in the state over the two-year study time 
period, regardless of where the individual was tested.  This major strength of our 
study enabled us to report accurate population-level rates of testing and 
positivity. 
Our study also meets key priorities of national strategies for chlamydia control. 
It provides the denominator data essential to measure testing at a population 
level, enables a comparison to be made with the level of testing required to 
reduce chlamydia prevalence and evidence to evaluate prevention programs.  
Our methods could be applied in other geographical areas, to enable the 
monitoring of testing trends, and to inform targeted testing of priority 
populations. 
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Our study had several limitations.  Our data reflects the population who were 
offered a test or who decided to get tested, and not necessarily the distribution of 
disease in the population. The IRSD decile scores used for the analysis of 
socioeconomic indicators were based on the 2011 SEIFA and we were unable to 
adjust for any changes that occurred in the population between 2011 and our 
study period (2012 and 2013).  Analysis of socioeconomic indicators was limited 
to tests conducted in private laboratories, and it is likely that people who 
experience socioeconomic disadvantage are more dependent on public health 
care (11). The majority of tests in our study (74%) were conducted in private 
laboratories, minimising this limitation.  
Our study was based on the population in Tasmania, and it is therefore not 
known whether the findings can be extrapolated to other jurisdictions.  However 
as linkage of all chlamydia tests conducted in a population has not been reported 
previously and our sample size is larger than that reported by some sentinel 
surveillance activities (9, 14), our findings are informative. Tasmania’s 
chlamydia notification rates in 2012 (348 per 100,000 population) and 2013 
(300 per 100,000 population) were similar to those reported in other states 
(with the exception of the Northern Territory), particularly the eastern states 
(range: 292 to 361 per 100,000 in 2012, and 281 to 341 per 100,000 in 2013) 
(7), suggesting chlamydia infection and testing patterns might be similar across 
most jurisdictions. 
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5.3.4 Recommendations 
An increase in annual testing of 15-24 year olds is needed, with a particular focus 
on people from disadvantaged areas and males, and on sustained testing of more 
than 30% of females aged 20-24 years.  
Improving chlamydia knowledge may increase testing rates (24).  Testing 
increases when clinician knowledge of testing guidelines improves (24), and 
acceptability of testing by young people is associated with increased knowledge 
about the asymptomatic nature of chlamydia, the potential sequelae and the 
simplicity of the testing process (25).  Normalisation of testing is imperative to 
address stigma (24, 25); and addressing concerns about privacy, embarrassment 
and confidentiality may increase the likelihood of young people seeking or 
agreeing to a chlamydia test (21). 
A considerable increase in testing could also be achieved by a change in how 
specimens are collected at some general practitioner (GP) clinics.  Lau et al 
(2016) found that in 20% of young people for whom GPs requested a test, a 
specimen was not submitted; and the odds of not undertaking a test was 40% 
higher in clinics without on-site specimen collection (21).  GPs are the main 
providers of sexual health services in Australia (1), therefore if this non-
compliance in young people was able to be overcome, there would be a 
significant improvement in testing rates in this priority population.  A sample 
from the first 10-20 millilitres of urine passed, taken at least 20 minutes post last 
void, is adequate for PCR testing; therefore, in most instances, specimen 
collection at time of consultation is achievable (26). 
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The burden of increased testing on general practitioners could be lessened by 
practice nurses playing a greater role (22), and by exploring alternative options 
to deliver testing in settings such as community pharmacies (23), which could 
also assist with lack of access to services. 
5.3.5 Summary 
We linked all chlamydia laboratory tests conducted over a two-year period and 
found that Tasmanian chlamydia testing coverage rates are below those 
recommended by clinical guidelines, particularly in males and people living in 
disadvantaged areas.  Based on mathematical modelling estimates, overall 
testing rates remain too low to impact on prevalence in the short-term, however 
sustained testing rates in females aged 20-24 years may reduce prevalence over 
the next decade.  
Our study provides valuable evidence to guide clinical practice and to inform 
national strategies.  Our study method could be applied in other geographical 
areas, to enable the monitoring of testing trends, and to inform targeted testing 
of priority populations in areas of greatest need. 
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Chapter 6 
_______________________ 
Geographical differences in Chlamydia 
trachomatis testing in 15-29 year-olds 
in Tasmania: findings from a statewide 
laboratory data linkage study. 
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6 Chapter 6 —  Geographical differences in Chlamydia 
trachomatis testing in 15-29 year-olds in Tasmania: 
findings from a statewide laboratory data linkage 
study 
6.1 Preface 
Lower chlamydia testing rates have been reported in areas in Australia with less 
access to services.  Under Australian Bureau of Statistics’ classification 
structures, Tasmania has no major cities and its mainland population resides 
mostly in inner and outer regional areas with a small proportion residing in 
remote areas.  Due to its small geographical size compared to other Australian 
states, it has been suggested that chlamydia testing rates in Tasmania are less 
influenced by geographic location. 
In this chapter, we describe geographical differences in chlamydia testing in 
young people in regional and remote Tasmania and provide a resource to guide 
clinical practice in the state. 
This paper has been accepted for publication in the Australian Journal of Rural 
Health and is currently awaiting allocation to an issue. 
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6.1.1 Summary 
What we already know? 
• Chlamydia is Australia's most frequently notified communicable disease, 
and people aged 15 to 29 years account for 80% of cases. 
• Chlamydia is associated with short- and long-term sequelae including 
infertility and increased risk of other sexually transmissible infections. 
• Reducing transmission of chlamydia is a priority under Australia’s 
National Sexually Transmissible Infections Strategy 2014-2018 and is 
critically dependent on adequate levels of testing and treatment of 
positive cases. 
• Under the national strategy, 15-29 year olds are a priority population for 
chlamydia testing. 
• The national strategy reinforces the need to address inequality in health 
and community care, including that related to geography. 
 
What does this paper add? 
• Provides state population level chlamydia testing rates in the at-risk age 
group of 15 to 29 years, by geographic location. 
• Provides a method of monitoring chlamydia testing at a population level. 
• Provides feedback to healthcare practitioners, particularly general 
practitioners who are the main providers of sexual health services in 
Australia. 
• Provides a method of measuring testing rates by geographic location, to 
allow health inequalities to be addressed. 
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6.2 Introduction 
Clinical guidelines for testing for Chlamydia trachomatis (chlamydia) infection 
recommend annual screening of all sexually active people aged 15 to 29 years(1).  
Lower chlamydia testing rates have been reported in areas in Australia with less 
access to services(2).  The Australian Bureau of Statistics’ (ABS) Remoteness 
Structure of the Australian Standard Geographical Standard divides Australia 
into regions that share common characteristics of remoteness (3). Under the ABS 
structure, Tasmania has no major cities and its mainland population is classified 
as residing mostly in inner (65%) and outer (33%) regional areas with a small 
proportion (1.5%) residing in remote areas (3).  Due to its small geographical 
size compared to other Australian states, it has been suggested that chlamydia 
testing rates in Tasmania are less influenced by geographic location (4), however 
this has not been previously explored at a state-wide level. 
The aim of this study was to describe geographical differences in chlamydia 
testing in young people in regional and remote Tasmania to inform clinical 
practice.  
6.2.1 Participants, methods and results 
Records of chlamydia tests conducted in 2012 and 2013 in residents of Tasmania 
aged 15 to 29 years were collected from all laboratories and made available to 
the Tasmanian Data Linkage Unit (TDLU). Test records were assigned a 
remoteness classification based on the ABS structure and postcode of residence 
at time of test. Population denominators were also obtained from the ABS.  Data 
linkage was conducted at the TDLU. Ethical approval was received from the 
Tasmanian Health and Medical Human Research Ethics Committee.  
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We conducted analyses on all tests, and by laboratory type.  We measured the 
number and rate of tests by remoteness classification, using Stata version 14.1 
(Stata Corporation, College Station, TX, US). Laboratory type was used as a proxy 
for type of diagnosing healthcare provider. 
There were 32,791 tests conducted in 24,753 individuals; 74% (n=24,266) in 
private and 26% (n=8,525) in public laboratories.  The population testing rate 
was 13% (24,753/188,772). Testing rates were higher in inner regional areas 
(15%; 18,973/122,888) compared to outer regional (9%; 5555/62930) and 
remote areas (8%; 225/2954) (p<0.001); and higher in females (21%; 
n=19,340) than males (6%; n=5,413) (p<0.001). A higher proportion of tests in 
individuals were conducted in private laboratories (76%, n=18,698) than in 
public laboratories (24%, n=6,055) (p<0.001), and this difference was greater in 
outer regional and remote areas (Table 6.1) 
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Table 6.1: Rates of chlamydia testing in males and females aged 15 to 29 years in Tasmania in 2012 and 2013, by remoteness 
classification† and type of laboratory 
    
All tests Tests in private laboratories  
Tests in public 
laboratories 
Private compared to public 
laboratories 
  
Population  Individuals
‡ 
tested  
Testing 
rate 
Individuals‡ 
tested  
Testing 
rate 
Individuals‡ 
tested  
Testing 
rate OR (95% CI) p-value 
Remoteness 
classification   n (%)   n (%)   n (%)       
Males                    
Inner regional 63,520 (65%) 4,177 6.6% 2,950 4.6% 1,227 1.9% 2.5 (2.3-2.6) <0.001 
Outer regional 32,220 (33%) 1,199 3.7% 1,123 3.5% 76 0.2% 15.3 (12.1-19.5) <0.001 
Remote 1,550 (2%) 37 2.4% 37 0.3% 0 0.0% - - 
Total 97,290 (100%) 5,413 5.6% 4,110 4.2% 1,303 1.3% 3.2 (3.0-3.5) <0.001 
Females                    
Inner regional 59,368 (65%) 14,796 24.9% 10,570 17.8% 4,226 7.1% 2.8 (2.7-2.9) <0.001 
Outer regional 30,710 (34%) 4,356 14.2% 3,832 12.5% 524 1.7% 8.2 (7.5-9.0) <0.001 
Remote 1,404 (2%) 188 13.4% 186 13.2% 2 0.1% 107.0 (29.1-891.5) <0.001 
Total 91,482 (100%) 19,340 21.2% 14,588 16.0% 4,752 5.2% 3.5 (3.3-3.6) <0.001 
†Based on the Remoteness Structure of the Australian Standard Geographical Standard(3); ‡ individuals counted once in a 12 month period, repeat tests removed. 
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6.2.2 Comment 
Chlamydia testing rates in the at-risk age group of 15 to 29 years are lower than those 
recommended under clinical guidelines, and people living in outer regional and remote 
areas of Tasmania are significantly less likely to be tested than those living in inner 
regional areas.   
Australian Institute of Health data shows that most testing initiated by general 
practitioners is conducted in private laboratories (5). The higher use of private 
laboratories for chlamydia tests conducted in people living in outer regional and remote 
areas in our study, supports earlier findings that people living in non-urban areas in 
Tasmania are predominantly diagnosed by general practitioners and significantly less 
likely to attend sexual health or family planning clinics for diagnosis than their urban 
counterparts (6).  
General practitioners (GPs) play a critical role in the diagnosis of chlamydia infections 
(6).  GPs in outer regional and rural areas in Tasmania should strive to increase their 
chlamydia testing in the at-risk age group of 15 to 29 years, particularly in males, and 
need to be aware of the possibility that young people may be reluctant to attend for 
sexual health testing. Alternatives such as visiting services, point of care testing and 
teleconsultation services may improve testing rates for young people who live in areas 
with less access to services. 
6.2.3 Limitations 
Some people tested at public laboratories may have been allocated the postcode of 
sexual health services, corrective services and youth centres rather than their postcode 
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of residence.  This limitation may have increased the proportion reported to be tested in 
inner regional areas.  
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Chapter 7 
_______________________ 
Chlamydia retest and retest positivity 
rates:  results from a state-wide 
laboratory data linkage study in 
Tasmania, 2012-2013 
 
Stephens N, Coleman D, Shaw K, O’Sullivan, Cooley L, McGregor A, Venn A. 
Chlamydia retesting and retest positivity rates: results from a state-wide laboratory 
data linkage study in Tasmania, 2012-2013.  Submitted to Sexual Health and is 
currently under review. 
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7 Chapter 7 — Chlamydia retest and retest positivity 
rates:  results from a state-wide laboratory data 
linkage study in Tasmania, 2012-2013 
7.1 Preface 
Young people aged 15 to 29 years account for the majority of notified cases of 
chlamydia and they are also more likely to be reinfected than older age groups.  
Reinfection with chlamydia increases the likelihood of developing pelvic 
inflammatory disease, ectopic pregnancy and infertility. 
Clinical guidelines recommend repeat resting to check for reinfection between 3-
12 months post initial treatment. 
In this chapter, we report on a data linkage analysis of the results of all 
chlamydia tests conducted in people aged 15 to 29 years resident in Tasmania, to 
assess the level of retesting and retest positivity in young people who previously 
tested positive for chlamydia infection. 
This paper has been submitted for publication to Sexual Health and is currently 
under review. 
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7.2 Abstract 
7.2.1 Background 
Chlamydia reinfection increases the likelihood of developing adverse long-term 
sequelae.  Clinical guidelines recommend retesting at 3-12 months for 
individuals with positive results, to detect reinfections.  We measured retesting 
and test positivity levels in young people who previously tested positive for 
chlamydia infection. 
7.2.2 Methods 
We linked all chlamydia tests conducted during 2012-2013 in Tasmanian 
residents aged 15-29 years. Retest and retest positivity rates were calculated by 
sex, age, socioeconomic indicators and test timeframe.  
7.2.3 Results  
Retest rates were higher in females than males at three months (14%, 
n=242/1673 v 10%, n=71/721) (p<0.01) and 12 months (27%, 265/968 v 24%, 
98/410) (p=0.24).  The retest rate was higher in females living in areas of most 
disadvantage (35%, 154/434) compared with areas of middle and least 
disadvantage (26% 139/534) (p<0.01).  No significant differences in retest rates 
were found in males, by area. 
Males were more likely than females to retest positive at three months (35%, 
25/71 v 23%, 55/242) (p<0.01); retest positivity at 12 months was 32% in both 
sexes (males 98/140; females 265/968).  Retest positivity was higher in males 
living in areas of least disadvantage (43%, 3/7) compared with middle (24%, 
16/67) (p=0.27) and most (27%, 10/37) (p=0.09); and retest positivity was 
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higher in females living in areas of least disadvantage (39%, 7/18) compared 
with middle (24%, 29/121) (p<0.01) and most (31%, 48/154) (p=0.02). 
7.2.4 Conclusions 
Retesting rates in people previously diagnosed with chlamydia are low in 
Tasmania and retest positivity is high, reinforcing the importance of promoting 
safer sex practices to prevent reinfection, partner notification and treatment, and 
retesting to minimise the risk of long-term sequelae. 
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7.3 Introduction 
Chlamydia trachomatis (chlamydia) is Australia’s most frequently notified 
communicable disease (1) and untreated infection is associated with significant 
short- and long-term morbidity including adverse reproductive outcomes and 
increased transmission of other sexually transmissible infections (2).  
Individuals who test positive for chlamydia are at an increased risk of 
subsequently testing positive (3-5) and reinfection in females increases the 
likelihood of developing pelvic inflammatory disease, ectopic pregnancy and 
infertility (4-8).   
Young people aged 15 to 29 years account for the majority of notified cases of 
chlamydia (9), and they are also more likely to be reinfected than older age 
groups (3, 10).  A cohort study conducted in primary care clinics across three 
jurisdictions in southeast Australia found that 22% of women aged 16 to 25 
years had a repeat infection within 12 months (11). In data reported by sentinel 
surveillance in Australia in people aged 16 to 29 years, retest positivity rates 
were variable.  Between 1.5 and 4 months post initial positive test, retest 
positivity was reported as 38% in males and 13% in females reattending general 
practice (12) and 25% in males and 12% in females reattending family planning 
clinics (13).  Between 1.5 and 12 months post initial positive test, retest 
positivity was 42% in males and 10% in females reattending general practice 
(12) and 33% in males and 13% in females reattending family planning clinics 
(13).  In people aged less than 30 years reattending sexual health services, retest 
positivity between 1 and 4 months post initial positive test was 44% in men who 
  156
have sex with men, 21% in heterosexual males and 16% in heterosexual females 
(14).    
The Royal Australian College of General Practitioners (15) recommends annual 
screening of all sexually active young people aged 15-29 years, and, if chlamydia 
infection is found, repeat testing to check for reinfection between 3-12 months.  
The Australian STI Management Guidelines (16) recommend retesting at three 
months for those with positive results to detect reinfections, and advises against 
a routine test for cure (with the exception of pregnant women and cases of rectal 
chlamydia). Sentinel surveillance in Australia has reported retesting rates within 
four months of initial positive test as between 9%-14% in males and 13%-29% 
in females (12,13,14); and within 1.5-12 months, as 22%-25% in males and 
36%-46% in females (12,13).  Retesting before four weeks post treatment is not 
recommended because of the risk of a false positive result due to the presence of 
chlamydia DNA remnants (16, 17).  Furthermore, most post-treatment infections 
do not result from treatment failure but from reinfection from either an 
untreated partner or sexual activity with a new infected partner (7, 8, 18).  The 
median length of time to reinfection has been reported as 4.6 months, with 50% 
of reinfections acquired between 3.5 to 6.6 months after initial infection (11).   
We undertook data linkage of all chlamydia tests conducted by public and 
private laboratories in people aged 15-29 years in the island state of Tasmania 
over a two-year period.  Our study design enabled us to include every test 
conducted in the population and to link individuals who may have been tested 
more than once, by more than one healthcare provider and in more than one 
laboratory. The aims of our study were to measure the level of retesting and 
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retest positivity in young people who previously tested positive for chlamydia 
infection, and to provide evidence to inform the clinical treatment of young 
people diagnosed with chlamydia. To the best of our knowledge, this is the first 
time in Australia that these types of analyses have been reported at a whole of 
state population level. 
7.3.1 Methods 
7.3.1.1 Study population and laboratory testing data 
Records of all chlamydia tests conducted from 1 January 2012 to 31 December 
2013 in residents of Tasmania aged 15 to 29 years were collected from all public 
and private laboratories and made available to the Tasmanian Data Linkage Unit 
(TDLU)(16).  
7.3.1.2 Data linkage  
Data linkage was conducted at the TDLU through a process of ‘Probabilistic 
Linkage’ which involved linking the data sets using a combination of unique 
identifiers together with a base level of administrative variables including name, 
address, date of birth and sex with the requirement that records being compared 
agree on all characters. Unique patient identifiers were created and a de-
identified dataset made available to researchers for the purpose of analysis that 
included the following variables: laboratory identifier, unique patient identifier, 
postcode of residence, date of birth, sex, and result of test. 
 
Socioeconomic indicators 
Individuals were assigned an Index of Relative Socioeconomic Disadvantage 
(IRSD) decile score as prescribed under the 2011 Socio-economic Indexes for 
  158
Areas (SEIFA), based on their postcode of residence.  SEIFA is a product 
developed by the Australian Bureau of Statistics that ranks areas in Australia 
according to their relative socio-economic advantage and disadvantage.  The 
population-based IRSD deciles represent groups of individuals who live in 
similarly ranked areas. IRSD scores range from 1 to 10, with 1 being the most 
disadvantaged relative to the other deciles (19). For analysis purposes, IRSD 
scores were categorised into three groups based on deciles 1 and 2 (most-
disadvantaged areas), 3 to 8 (middle-disadvantaged areas) to 9 and 10 (least-
disadvantaged areas).  Socioeconomic indicator analysis was restricted to people 
tested at private laboratories.  Postcodes of people tested at public laboratories 
were unreliable due to an unknown proportion allocated the postcode of sexual 
health services, corrective services and youth centres 
7.3.1.3 Analysis  
We classified the first positive chlamydia test in an individual conducted within 
the study time period as their “initial” positive test.  Retest rates and retest 
positivity rates were calculated for individuals with an initial positive test 
between 1 January 2012 and 31 August 2013, based on their first retest. Rates 
were calculated at 4-weekly timeframes from 4 to 16 weeks post initial positive 
test.  A 3-month retest rate was classified as any retest occurring between ≥8 
weeks and ≤16 weeks post initial positive test.  Tests conducted within four 
weeks of an initial positive test (females n=91; males n=21) were not considered 
due to the possibility of false positive results (16,17). 
To allow a full 12-month period post initial positive test, 12-month retest rates 
and retest positivity rates by agegroup, sex and disadvantage score were 
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calculated for those individuals with their initial positive test notified between 1 
January 2012 and 31 December 2012. A 12-month retest rate was classified as a 
retest occurring between ≥4 weeks and ≤52 weeks post initial positive test.  
The total numbers of retests conducted in males and females were also 
measured, again by 4-weekly timeframes from 4 to 16 weeks for all people, and 
between 16 and 52 weeks for those with an initial positive test in 2012. 
Population denominators were derived from the estimated resident population 
of each collection district obtained from the Australian Bureau of Statistics for 
2012 and 2013 Positivity rates were calculated by dividing the number of 
positive tests by the number of tests conducted.   Data were analysed using Stata 
version 14.1 (Stata Corporation, College Station, TX, US).  Differences in 
proportions were considered significant at p<0.05. 
7.3.1.4 Ethical approval 
This study was approved by the Tasmanian Health and Medical Human Research 
Ethics Committee. 
7.3.2 Results 
7.3.2.1 Retesting rates 
A total of 31,899 nucleic acid tests were conducted in 24,830 individuals 
between 1 January 2012 and 31 August 2013.  Of those, a total of 1,673 females 
and 721 males tested positive between 1 January 2012 and 31 August 2013.  The 
retest rate at the recommended 3-month timeframe was significantly higher in 
females (14%, n=242) than in males (10%, n=71) (p<0.01).  The retest rate 
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between 1-4 months was also higher in females (21%, n=349) than males (18%, 
n=128) (p=0.09) (Table 7.1).  
Amongst the 2012 cohort, the retest rate during the period 1-12 months post 
initial positive test was slightly higher in females (27%, n=265/968) than in 
males (24%, n=98/410) (p=0.24).  By timeframe of test, the highest retest rates 
in females were found in weeks 16-52 (16%) and weeks 8-12 (9%), and in males 
in weeks 16-52 (12%) and weeks 4-8 (8%) (Table 7.1).  
7.3.2.2 Demographic differences in retesting rates 
Higher levels of retesting were observed in males living in areas of middle 
disadvantage, compared with retesting of males living in areas of most or least 
disadvantage, however the differences were not statistically significant between 
any of the groups.  There was significantly more retesting in females living in 
areas of most disadvantage compared with females living in areas of middle and 
least disadvantage (p<0.01) (Figure 7.1). 
  161 
Table 7.1: Retest rates and retest positivity rates* in individuals aged 15 to 29 years resident in Tasmania with an initial 
positive chlamydia test between 1 January 2012 to 31 August 2013  
  
Individuals 
with an 
initial 
positive test, 
N 
4-<8 weeks 8-<12 weeks 12-≤16 weeks 3-month retest^ 16-≤52 weeks~ 12-month retest~ 
Individuals, n (%) Individuals, n (%) Individuals, n (%) Individuals, n (%) Individuals, n (%) Individuals, n (%) 
Males   Retested Positive Retested Positive Retested Positive Retested Positive Retested Positive Retested Positive 
15-19 yrs 229 21 (9%) 2 (10%) 13 (6%) 6 (46%) 13 (6%) 2 (15%) 26 (11%) 8 (31%) 11/136 (8%) 2 (18%) 35/136 (26%) 9 (26%) 
20-24 yrs 353 25 (7%) 5 (20%) 19 (5%) 9 (47%) 15 (4%) 8 (53%) 34 (10%) 17 (50%) 19/190 (19%) 4 (21%) 36/190 (19%) 14 (39%) 
25-29 yrs 139 11 (8%) 1 (9%) 7 (5%) 0 (0%) 4 (3%) 0 (0%) 11 (8%) 0 (0%) 16/84 (19%) 6 (38%) 27/84 (32%) 8 (30%) 
Females                           
15-19 yrs 785 55 (7%) 7 (13%) 68 (9%) 13 (19%) 45 (6%) 15 (33%) 113 (14%) 28 (25%) 80/474 (17%) 28 (35%) 139/474 (29%) 47 (34%) 
20-24 yrs 681 37 (5%) 6 (16%) 52 (8%) 8 (15%) 42 (6%) 12 (29%) 94 (14%) 20 (21%) 64/379 (17% 16 (25%) 94/379 (25%) 29 (31%) 
25-29 yrs 207 15 (7%) 3 (20%) 24 (12%) 6 (25%) 11 (5%) 1 (9%) 35 (17%) 7 (20%) 14/115 (12%) 3 (21%) 32/115 (28%) 8 (25%) 
                
    
    
    
All 
males 721 57 (8%) 8 (14%) 39 (5%) 15 (38%) 32 (4%) 10 (31%) 71 (10%) 25 (35%) 46/410 (11%) 12 (26%) 98/140 (24%) 31 (32%) 
All 
females 1673 107 (6%) 16 (15%) 144 (9%) 27 (19%) 98 (6%) 28 (29%) 242 (14%) 55 (23%) 158/968 (16%) 47 (30%) 265/968 (27%) 84 (32%) 
*Retested between ≥4 and ≤52 weeks post initial positive test; ^≥8 and ≤16 weeks post initial positive test; ~calculated on 2012 cases only 
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Figure 7.1: Proportion of males and females aged 15 to 29 years tested in private laboratories with an initial positive 
chlamydia test between 1 January 2012 and 31 December 2012, who were subsequently retested for chlamydia, by IRSD score* 
*Australian Bureau of Statistics’ IRSD scores(19) range from 1 to 10, with 1 being the most disadvantaged relative to the other deciles. For analysis purposes, IRSD decile scores were divided into three 
groups, ranging from 1 and 2 (most disadvantaged areas, population 195,867), 3 to 8 (middle disadvantaged areas, population 255,377) to 9 and 10 (least disadvantaged areas, population 42,947).  
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7.3.2.3 Positivity rates at retest 
The majority of reinfections were found between weeks 12 and 16 in both males 
(55%) and females (52%) (Table 7.1).   
Males were more likely than females to test positive in retests conducted 
between 4 and 16 weeks post initial positive test (p=0.03) (with the exception of 
retests conducted at 4-8 weeks), and at the 3-month timeframe (males 35%, 
females 23%) (p<0.01).  By agegroup and sex, the highest rates of reinfections at 
3 months were found in males aged 20-24 years (50%) followed by males 15-19 
years (31%) and females 15-19 years (25%) (Table 7.1).   
There was no overall difference between male and female retest positivity in 
those who were retested between 4-52 weeks after their initial positive test 
(both 32% positivity).  By age group and sex, males aged 20-24 years continued 
to have the highest rates of reinfection (39%), followed by females 15-19 years 
(34%) and females 20-24 years (31%) (Table 7.1).  
7.3.2.4 Demographic differences in retest positivity 
Males living in least disadvantaged areas were more likely to retest positive than 
males living in middle disadvantaged areas (p=0.04) and most disadvantaged 
areas (p=0.09).  Females living in least disadvantaged areas were more likely to 
retest positive than females living in most (p=0.02) and middle (p<0.01) 
disadvantaged areas (Figure 7.1). 
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7.3.2.5 All retests 
A total of 1,208 retests in 598 females, and 287 retests in 195 males, were 
conducted over the study period.  Females were more likely than males to have 
multiple retests up to 16 weeks (p<0.01).  There was no significant difference 
between the sexes in having multiple retests conducted between 4 and 52 weeks 
(Figure 7.2).   
 
Figure 7.2: Number of retests in individuals and overall number of retests 
between 4 and 52 weeks post initial positive chlamydia test, in residents of 
Tasmania aged 15 to 29 years with an initial positive test for chlamydia 
between 1 January 2012 and 31 August 2013 
*calculated on cases with initial positive test between 1 January 2012 and 31 December 2012 
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7.3.3 Discussion 
7.3.3.1 Retesting rates and reinfections  
In this whole of state population-based data linkage study, we measured 
chlamydia retest rates and retest positivity rates in individuals aged 15 to 29 
years resident in Tasmania who had previously tested positive for chlamydia.  
Rates of retesting at the recommended 3-month timeframe (15, 16) were low in 
both males (10%) and females (14%); and, despite an increase when measuring 
retests up to 12 months post initial positive test, the retest rates remained low 
(males 24%; females 27%).  Retest positivity was high in both males and females 
at the 3-month retest timeframe (35% and 23% positivity, respectively), and at 
the 12-month retest timeframe (both 32% positivity).  These reinfection rates 
are significantly higher than the annual chlamydia positivity rates observed in 
the same population over the same time period (males 6%; females 21%) (both 
p<0.001) (20).  The majority of reinfections were detected between 12 and 16 
weeks post initial positive test, highlighting this timeframe as the most 
appropriate period for retesting.   
The low retest rates and high retest positivity rates are of considerable concern 
due to the increased risk of long-term sequelae in people with chlamydia 
reinfections.   
7.3.3.2 Demographic differences in retesting rates and reinfections 
The higher levels of retesting in females living in areas of most disadvantage 
might be explained by the cost of attending a medical appointment. Data 
collected as part of a census of Tasmanian general practices in 2014 (21) shows 
that general practitioners (GPs) practicing in areas of most disadvantage are 
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significantly more likely to offer bulk billinga to their patients than GPs practicing 
in areas of least disadvantage (50%, n=45/90 practices; compared with 31%, 
n=17/55 practices) (p=0.02) (unpublished data, Primary Health Tasmania); and 
a community-based Australian survey conducted in 2013 found that people with 
lower income levels were significantly more likely to be offered bulk billing (23). 
Therefore, females living in areas of least disadvantage are less likely to be 
offered bulk billing, and the cost of an appointment for the purpose of a retest 
may be prohibitive for this cohort.  
In both males and females, retest positivity was higher in individuals living in 
areas of least disadvantage.  Reasons for this discrepancy could include higher 
levels of health literacy and health-seeking behaviour (24) in people living in 
areas of least disadvantage, which may result in those at higher risk of 
reinfection self-presenting for retesting.  Also, people living in most 
disadvantaged areas are less likely to have long GP consultations than people 
living in more advantaged areas (25).  A shorter consultation could impact on the 
ability of GPs to ensure their patients are aware of the need for retesting when at 
high risk of reinfection, and may also result in GPs having less knowledge of the 
patients’ risk histories.   
7.3.3.3 Comparison with other Australian studies  
Our retest rates in males were very similar to the retest rates reported by 
sentinel surveillance in Australia, both at 3-month retest (our rate 10%, sentinel 
surveillance rate 9%-14% (12-14)) and at 12-month retest (our rate 24%, 
                                                        
a Bulk billing is when health professionals accept the Medicare benefit as full payment for a 
service (22). 
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sentinel surveillance rate 22%-25% (12, 13)).   Our male retest positivity at 3-
month retest was mid-range of that reported by sentinel surveillance (35% 
compared with 21%-44%(12-14)) and slightly lower at 12-month retest (32% 
compared with 33%-42% (12, 13)). 
Our retest rates in females of 14% at 3-month retest and 23% at 12-month retest 
were lower than the female retest rates reported by sentinel surveillance (13%-
29% (12-14) and 36%-46% (12, 13), respectively).  Our female positivity at 
retest, however, was considerably higher at both the 3-month retest (23%) and 
12-month retest (32%) compared with the rates reported by sentinel 
surveillance (12%-16% (12-14) and 10%-13% (12, 13)), and higher than the 
rate of 22% reported by an Australian cohort study (11).  
There are several differences between our study and the cohort study and 
sentinel surveillance that might explain these varied findings.  The main 
difference is that our study was based on a whole state population, whereas the 
cohort study and sentinel surveillance were based on population samples and 
may have been biased by selection factors.  The study and sentinel surveillance 
rates are based on the person reattending the same clinic, whereas, in our study, 
we captured every test in every individual regardless of where they attended 
and linked them to enable us to report a population rate.  It is possible that retest 
and retest positivity rates were underestimated in the study and sentinel 
surveillance data, through failure to capture patients retesting at more than one 
clinic site.  It is also possible that retest rates and retest positivity are different in 
Tasmania than in the areas reported by the cohort study and sentinel 
surveillance. 
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7.3.3.4 Potential reasons for low retesting rates 
There are several potential explanations for the low retesting rates, including 
clinical discretion.  Clinicians may be selecting those at highest risk of reinfection 
(targeted retesting) and retesting them often.  Our results show high retest 
numbers in individuals retested for chlamydia and support this assertion.   
Patients themselves may be self-selecting, based on their self-assessed risk.  As 
chlamydia is asymptomatic in up to 80% of cases, there is a risk that 
asymptomatic people may not see themselves as high risk and they may be less 
likely to present for a retest (18) and some patients may not perceive retesting 
as a priority, leading to variation in patient adherence to recommendations to 
retest (14).  However, findings of a study in the United Kingdom are encouraging.  
They showed that a quarter of patients that did not consent to a reminder to 
retest accurately assessed their own risk and sought chlamydia retesting 
actively, and were more likely to be infected than those who had consented to be 
contacted (4).   
The high retest positivity rates found in our study support the hypotheses of 
targeted testing by clinicians and self-selection for retesting by high-risk 
patients. 
7.3.3.5 Ways to increase retesting rates   
Retesting rates improve significantly when SMS reminders are sent to patients 
(4, 14) and, for some patients, retesting rates increase even more when 
combined with the provision of home kits for self collection of samples (14, 18, 
26).  Home test kits also alleviate another one of the barriers to retesting – the 
time and effort involved in going back to the clinic (27). Social circumstances 
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impact patients’ retesting preferences, therefore providing choice of retesting 
methods is important (4, 12, 18). 
Actions taken by clinics can also improve retest rates, such as robust data 
systems to enable auditing of retests (4, 16) and increasing clinicians’ knowledge 
about management of chlamydia infections (28).  Practice nurses could also play 
a more active role in chlamydia retesting (28). 
7.3.3.6 Strengths and limitations 
The greatest strength of our study was that it was based on the whole population 
of 15 to 29 year-olds living in Tasmania.  The linkage of all individuals’ chlamydia 
tests enabled us to report accurate population-level retesting and retest 
positivity rates.  Retesting is vital to identifying and treating repeat infections 
(18) and our paper provides an accurate feedback mechanism to clinicians on 
their retesting efforts. 
Our study had several limitations.  Our data reflects the population who were 
offered a retest or who decided to get retested, and not necessarily the 
distribution of reinfection in the population.  Our study was based on the 
population in Tasmania, and it is not known whether the findings can be 
extrapolated to other jurisdictions.  However, our sample size is large and as this 
is the first study to report retest and retest positivity rates at a state-population 
level, our findings are informative.  Tasmania’s chlamydia notification rates in 
2012 and 2013 were very similar to those reported in other eastern Australian 
states (29), suggesting infection and testing patterns are similar across 
jurisdictions.   
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7.3.3.7 Recommendations 
It is important that clinicians treating patients with chlamydia infections ensure 
their patients are aware of the potential consequences of reinfection including 
the increased risk of long term sequelae such as infertility.  Clinicians should also 
educate their patients on safer sex behaviours to prevent reinfection, 
particularly the importance of the use of condoms (30).   
Clinicians should seek guidance from their patients on the most appropriate way 
to ensure a retest occurs at 3-months post initial diagnosis. Practice nurses could 
be engaged to assist with the retest workload in clinics, and reminder systems 
within clinics could ensure follow up of at risk patients occur. 
Clinicians could focus their retesting efforts at 12 to 16 weeks post treatment, to 
prevent excess retesting of individuals at timeframes when reinfections are less 
likely to be detected.  Continued clinical discretion can ensure adequate levels 
and frequency of retesting in those at highest risk.  Where possible, clinicians 
should offer bulk billing at time of retest.  
7.3.3.8 Summary 
We linked all chlamydia tests conducted over a two-year period to individuals 
and found that retesting rates of patients previously diagnosed with chlamydia 
are low, particularly at the recommended timeframe for retesting (3 months).  
Chlamydia retest positivity was high in both males and females, reinforcing the 
importance of increasing the use of condoms amongst priority populations to 
prevent reinfection, partner notification and treatment, and retesting to 
minimise the risk of long term sequelae. 
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Our study provides valuable evidence to inform clinical practice, and our 
methods could be applied in other geographical areas to enable the monitoring 
of retesting trends.  Our study also provides a method to monitor the proportion 
of chlamydia tests that yield a positive test in the 15-29 year age group, which is 
a priority under the National Blood-borne Viruses and Sexually Transmissible 
Infections Surveillance and Monitoring Plan 2014-2017 (30).  
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8 Chapter 8 — Discussion 
8.1 Introduction 
This thesis includes analyses of four datasets collected in Tasmania: i/ statutory 
data on all Chlamydia trachomatis (chlamydia) cases notified to the Tasmanian 
Department of Health and Human Services between 2001 and 2010; ii/ 
demographic and clinical information collected on all notified chlamydia cases 
between 2001 and 2010; iii/ the results of all chlamydia laboratory tests 
conducted in the state between 2001 and 2010; and iv/ the results of linked 
chlamydia laboratory testing data in 2012 and 2013.  The central aims of this 
research were to provide an evidence base from which prevention, intervention 
and control activities can be planned, monitored and evaluated; and methods 
that can be utilised in other geographical locations for the same purposes.  The 
following sections provide a summary of the key findings, the limitations of the 
study, and public health implications and outcomes. 
8.2 Summary 
The key findings and contributions to the literature from this dissertation are as 
follows: 
• This study was the first in Australia to provide a comparison of chlamydia 
notification rates by subgroups derived from a population-based dataset 
collected over a 10-year period (Chapter 2).  The study results 
demonstrated that the large majority of males (84%) and females (71%) 
notified with chlamydia were diagnosed by general practitioners; 
however the range and the differences between the sexes and across age 
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groups in choice of healthcare provider highlighted the importance of the 
availability of a variety of services.  We found females were more likely to 
have been tested for chlamydia infection as a result of screening (50%), 
whereas males were more likely to have been tested when presenting 
with symptoms (52%).  Our data demonstrated significant under-
reporting in males, highlighting the need for strategies to improve 
screening in males. 
• This study was the first in Australia to measure chlamydia test positivity 
at a population level over a 10-year period and compare the results to 
notification data (Chapter 3).  We found increases in chlamydia infections 
that remained after allowing for testing effort, inferring that the 
prevalence of chlamydia increased over the 10 years in Tasmania.  Large 
increases in testing occurred, particularly in young males, indicating that 
healthcare providers are striving to reach the testing goals and that the 
gender gap in testing practices is narrowing.  We demonstrated that the 
analysis of laboratory testing data is useful for surveillance purposes and 
can be achieved through an extraction of data routinely collected by 
laboratories.  Monitoring trends in population-level chlamydia testing is 
sustainable and could be included in public health surveillance activities. 
• This study was the first in Australia to examine the symptom status, 
reason for testing and sexual exposure of people aged 15 to 29 years 
notified with chlamydia over a 10-year period, and to compare the results 
to laboratory testing data conducted over the same time period (Chapter 
4).  A key public health goal, fundamental to the strategies to control the 
chlamydia epidemic in Australia, is to reach adequate levels of testing for 
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chlamydia in sexually active young people, both asymptomatic and 
symptomatic (1).  Our results showed that the proportion of diagnoses in 
asymptomatic people increased, with the largest increases observed in 
young males, and that the proportion of male cases tested as a result of 
screening also increased.  We found that after allowing for any changes in 
sexual exposure, symptom status and reason for testing, an increase in 
chlamydia test positivity occurred over the 10 years, and that healthcare 
providers have increased their chlamydia testing rates in high-risk 
groups. 
• For the first time in Australia, Chapter 5 reports the results of data 
linkage of all chlamydia testing conducted at a state population level over 
a two-year period.  Our study design enabled us to include every test 
conducted in the population and to link individuals who may have been 
tested more than once, by more than one healthcare provider and in more 
than one laboratory, enabling us to report true population rates of testing 
and test positivity.  We compared our results to clinical guidelines (2, 3) 
and to the estimated testing levels required to reduce chlamydia 
prevalence.  Chlamydia testing rates are lower than those recommended 
under clinical guidelines in both males and females; however, testing in 
females 20 to 24 years is approaching the estimated level required to 
reduce chlamydia prevalence over the next 10 years (4).   Our study 
provided a robust methodology that can meet the requirements of the 
Australian National Sexually Transmissible Infections Strategy (1) by 
monitoring testing coverage and providing evidence to evaluate 
prevention and control programs. 
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• Lower chlamydia testing rates have been reported in regional and rural 
areas in Australia due to less access to testing (5).  Tasmania’s population 
mostly resides in inner and outer regional areas (6), however due to its 
small geographical size compared to other Australian states, it has been 
suggested that chlamydia testing rates in Tasmania are less influenced by 
geographic location (7). This study (Chapter 6) provides evidence of 
testing levels at a geographical level in Tasmania and is a useful resource 
to guide clinical practice in the state.  We found that people living in outer 
regional and remote areas in Tasmania are significantly less likely to be 
tested than those living in inner regional areas.   
• Chlamydia reinfection increases the risk of long-term sequelae including 
adverse reproductive outcomes and increased transmission of other 
sexually transmissible infections (8); and individuals who test positive for 
chlamydia are at an increased risk of subsequently testing positive (9-11).  
For this reason, clinical guidelines (2, 3) recommend repeat testing of 
those with positive tests, to check for reinfection.  For the first time in 
Australia, this study of a whole population (Chapter 7) measured the 
level of retesting and retest positivity in young people who previously 
tested positive for chlamydia. We found retest rates at the recommended 
timeframe were low in both males (10%) and females (14%); and that 
test positivity was significantly higher than the annual chlamydia 
positivity rates found in the same population.  Our study provides 
important evidence to guide clinical practice and our methods could be 
applied in other geographical areas to enable the monitoring of retesting 
trends. 
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8.3 Limitations 
There are a number of potential limitations in this research that should be 
considered when interpreting the findings.   
Firstly, the data collected from notified cases in our study was based on 
individuals who were mostly tested as a result of symptomatic presentation or 
screening.  A large proportion of chlamydia infections are asymptomatic (4), 
therefore a large proportion of both males and females with chlamydia infections 
may not get diagnosed.  Any differences between individuals who were 
diagnosed and individuals who were not diagnosed are unknown. Additional 
surveillance data, beyond basic demographic details, was not collected for 15% 
of notified cases, however there were no differences found in the age, sex or 
geographic location of the cases for whom we collected data and for whom we 
did not, reducing the risk of selection bias. 
A range of commercial nucleic acid tests with minor variations in lower limits of 
detection were used in laboratories throughout the period of the study.  This 
may have had a small influence on the positivity rates.  Local and temporal 
changes in specimen type may also have impacted the detection rates (L. Cooley, 
Head of Microbiology, Royal Hobart Hospital, Tasmania, personal 
communication, 2014).   
In the unlinked laboratory data collected from 2001 to 2010, we found 7% more 
positive tests than notified cases over the same time period. This difference 
might be explained by the inclusion of repeat tests or underreporting in the 
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notification data.  The limitation was consistent over the 10 years and should not 
impact the observed trends.   
Our analyses of both the notification data and the unlinked laboratory data were 
limited by their deidentified nature.  We were unable to ascertain whether a 
person was tested or notified more than once in each year.  We addressed the 
limitation of deidentified data in our studies presented in Chapters 5, 6 and 7, in 
which we linked all testing data over a two-year period.  Still, as in previous 
chapters, the data reflected the population who were offered a test or who 
decided to get tested, and not necessarily the distribution of the disease in the 
population.   
Due to an unknown proportion of individuals tested at public laboratories being 
allocated the postcode of sexual health services, corrective services and youth 
centres, we restricted our socioeconomic indicator analysis to tests conducted in 
private laboratories. It is likely that people who experience socioeconomic 
disadvantage are more dependent on public health care (12) and this may have 
influenced the results.  We included public laboratory data in our geographical 
analysis, which may have inflated the proportion tested in inner regional areas. 
The descriptive analyses conducted on the data included in Chapters 5 and 7 
were adequate to meet the aims of the project, ie. to measure the rates of testing 
and retesting at a state-wide level in order to compare adherence to clinical 
guidelines and to compare to the projected levels required to reduce chlamydia 
prevalence.   Future research could be expanded to include exploration of 
alternative hypotheses, such as the impact of remoteness on testing levels, 
through multivariable regression analysis. 
  184
 
The research presented in this thesis is based on the population in Tasmania, 
and it is not known whether the findings can be extrapolated to other 
geographical areas.  However, Tasmania’s chlamydia notification rates are very 
similar to those reported in other eastern states of Australia (13) (Figure 8.1), 
suggesting chlamydia reinfection and testing patterns might be similar across 
jurisdictions.  Our sample size was also larger than that reported by sentinel 
surveillance activities, and our findings are therefore informative. 
 
Figure 8.1: Notification rate per 100,000 population, chlamydia infection, 
Australia, 2010 to 2014, by jurisdiction 
(Sourced from: Australian Government Department of Health, National Notifiable Diseases Surveillance System, available 
at: http://www9.health.gov.au/cda/source/cda-index.cfm) 
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8.4 Public health implications of this research 
8.4.1 Chlamydia surveillance 
Chlamydia notifications have been increasing since the condition first became 
notifiable in 1994 (Figure 8.2).  
 
Figure 8.2: Notification rate per 100,000 population, chlamydia infection, 
Australia, 1994 to 2014(13) 
(Sourced from: Australian Government Department of Health, National Notifiable Diseases Surveillance System, available 
at: http://www9.health.gov.au/cda/source/cda-index.cfm) 
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disease associated with infection and to reduce population prevalence.  These 
strategies include: primary prevention (health promotion, education, access to 
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epidemic and of particular relevance to the public health surveillance of 
chlamydia, include: i/ improving the surveillance of the incidence of chlamydia 
in priority populations, ii/ improving methods of monitoring testing coverage, 
and iii/ the development and promotion of nationally consistently STI testing 
and retesting guidelines (1).  The current method of conducting passive 
surveillance is inadequate and cannot meet these priority action items. Current 
surveillance is based on notifications of diagnosed cases (14) and does not 
provide the vital testing information needed to understand trends in notification 
data; inform, monitor and evaluate prevention and control activities; and 
monitor testing coverage.   The methods developed and presented in this thesis 
directly meet priorities i and ii described above, and provide evidence to guide 
the development of priority action iii. 
This study has shown it is possible, and a lot more useful, to monitor the 
proportion of positive tests and testing coverage by the collection, analysis and 
reporting of laboratory testing data.  By inclusion of sex, age and postcode with 
the result of test, it is possible to target interventions towards at risk groups.  
The methods presented in this dissertation would enable health authorities to 
conduct tight geographical analyses of laboratory data, and target interventions 
at a local level.  For example, an annual chlamydia testing rate of 30% in females 
aged 20 to 24 years is predicted to decrease the prevalence of chlamydia 
dramatically, with 50% of the decrease occurring in the first four years (4).  
Figure 8.3 shows the annual testing rate in 2012 and 2013 in females aged 20 to 
24 years by regions of Tasmania.  The map shows very clearly where particular 
focus and promotion of testing is required to increase testing to 30%.  Health 
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authorities could analyse testing data by an even smaller geographical area and 
then target their messages appropriately.  For example, analysis by local 
government area could be mapped and provided to: doctors practicing in areas 
with inadequate levels of testing to encourage them to increase their testing 
levels; local government to design campaigns promoting the importance of being 
tested; and local schools, colleges and universities to develop and implement 
education messages.   
 
Figure 8.3: Rate of chlamydia testing in females aged 20-24 years in 2012 
and 2013 in Tasmania, by region 
 
Collection of additional data on notified cases, such as symptom status (Chapter 
3) also meets a priority of the National Sexually Transmissible Infections 
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Strategy (1), that is, to identify and address emerging issues.  As chlamydia is 
mostly asymptomatic (15-17), regular testing of all sexually active young people, 
not just those who present with symptoms, is a vital component of strategies to 
increase testing efforts (1).   Our method of collecting additional data from the 
treating doctors of notified cases could be implemented in other Australian 
jurisdictions to monitor the level of testing in asymptomatic young people.  
Collection of additional surveillance data at a population level can be resource 
intensive in jurisdictions with large populations, however targeted periodic 
surveys could be implemented.     
Periodical data linkage should also play an important role in chlamydia 
surveillance.  Trends in testing rates can be monitored through analysis of 
deidentified laboratory datasets; however the gold standard in monitoring 
testing trends is linking tests conducted in individuals and reporting on 
population testing rates.  This type of analysis is resource intensive and 
potentially not feasible as a routine surveillance method in some jurisdictions.   
Under those circumstances, periodical data linkage would provide valuable 
evidence to support the routinely collected testing data, and is particularly 
important for monitoring what proportion of the population who test positive 
subsequently receive a retest. 
8.4.2 Application of the method to other disease surveillance 
Our methods would be equally valuable for surveillance of some other diseases, 
such as influenza.  Notification rates of influenza in Australia were relatively 
stable and below 50 cases per 100,000 population until 2006.  Since that time 
there has been a sharp increase in notification rates (Figure 8.4).  It has been 
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argued that the increase in influenza notifications is a testing artefact.   The 
introduction of an item number in the Australian Medicare benefits schedule in 
2004 (18) led to a steady increase in influenza testing.  This has been most 
evident from 2007 and is possibly linked to heightened awareness since the 
publicised deaths in children associated with influenza in 2007, and from the 
pandemic in 2009 (19).  At the same time, syndromic and hospital-based 
surveillance activities in Australia have indicated that there has not been a 
concomitant increase in influenza-like-illness burden or influenza disease 
severity (20).  As public health surveillance of influenza is also reliant on passive 
notification of diagnosed cases, the true impact of testing practices on rates over 
time cannot currently be measured. 
 
Figure 8.4: Notification rate per 100,000 population, influenza, Australia, 
2001 to 2015 
(Sourced from: Australian Government Department of Health, National Notifiable Diseases Surveillance System, available 
at: http://www9.health.gov.au/cda/source/cda-index.cfm) 
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Reporting under the current influenza surveillance system (passive reporting of 
diagnosed cases) not only limits the ability to plan, monitor and evaluate public 
health policies and interventions, but also creates an environment where 
misinterpretation occurs.  The large number of influenza notifications in recent 
years has led to increased media interest with headlines and articles that can 
create concern in the community (Figure 8.5). 
 
 
Figure 8.5: News Corp Australia Network. “Australia is in the grip of a flu 
explosion with diagnosed cases this year more than double the five year 
average and 2,000 people testing positive for the virus in the last week.”   
Available at: http://www.adelaidenow.com.au/news/national/flu-epidemic-hits-with-
diagnoses-running-at-double-the-average-for-this-time-of-year/news-
story/b7afb25d471d25eb8f1bffb1e6187deb 
As well as enabling a measured response to community concern about rising 
numbers of reported diagnoses, collection of high quality laboratory testing data 
for influenza is needed to enable monitoring and reporting of trends, and to 
gauge the timing and peak of the influenza season and to improve pandemic 
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preparedness activities (21).  The methods presented in this thesis would meet 
those needs. 
8.4.3 Legislative change 
In order to report on testing trends and test positivity, health authorities require 
the testing data from laboratories; that is, they require details of all negative 
tests, not just those of diagnosed cases.  Under current legislation in Tasmania, 
(the Public Health and Wellbeing Act 1997 and the Guidelines for Notifying 
Diseases and Food Contaminants (22)), laboratories are only required to notify 
the department when a person has evidence of a notifiable disease.  Similar 
legislation is in place in other states and territories in Australia.   
There are two options available, either an amendment to the Guidelines (22) to 
require laboratories to report negative tests; or, establishment of a 
Memorandum of Understanding between health authorities and laboratories to 
create an environment where laboratories are supported and secure in 
providing the data to health authorities. 
There are several overseas examples of health authorities successfully collecting 
laboratory data for chlamydia surveillance purposes.  In New Zealand (where 
chlamydia is not a notifiable condition), the health authorities receive laboratory 
testing data and measure trends in testing and test positivity for surveillance 
purposes (23, 24); and in the United Kingdom, chlamydia testing data is collected 
from all National Health Service (NHS) and NHS-commissioned laboratories.  
Norway implemented a laboratory based surveillance system in 2005, whereby 
they collect the total number of chlamydia tests performed and the number of 
diagnosed cases once a year from all laboratories, and in 2007 improved their 
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system to collection additional information on age, sex and geography in order to 
better interpret trends (25).  
8.5 Outcomes of this research  
To date, public health actions have been taken in both Tasmania and Victoria as a 
result of the findings of this research.   
Tasmania has changed its legislation to allow laboratories to notify chlamydia in 
a less resource intensive way than previously.  Prior to 2016, laboratories were 
required to notify individual diagnoses of chlamydia to the Tasmanian 
Department of Health and Human Services (DHHS).  The new Guidelines now 
allow a password protected spreadsheet of diagnoses found in the immediately 
preceding month to be forwarded to the DHHS  on the 5th working day of the 
month (26).  This initiative is progress towards an electronic method of 
notification, has resolved the considerable workload associated with notification 
of single diagnoses, and still allows the monitoring and reporting of notification 
trends.   
The Tasmanian DHHS is currently documenting its plans to continue to collect 
laboratory testing data and report on trends in testing and positivity.  These 
plans include bi-annual data linkage of laboratory testing data to enable ongoing 
monitoring, analysis and reporting of chlamydia testing, retesting and test 
positivity (personal communication, Senior Surveillance Officer, DHHS).  This 
will enable ongoing, targeted public health prevention and control activities to 
be undertaken; and for advice to be provided to Tasmanian clinicians on where 
they need to focus their testing, based on accurate, population-level data.  The 
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new method in Tasmania will be in line with that presented in Chapters 5, 6 and 
7 of this thesis. 
In Victoria, a larger southern state of Australia with a population of 
approximately 6 million, the Victorian Department of Health and Human 
Services has commenced negotiations with pathology laboratories to seek 
chlamydia testing results on a quarterly basis.  The data to be collected will 
include age, sex, postcode and result of test for both diagnosed cases and for 
negative tests.  This will enable Victoria to monitor, analyse, report and target 
their public health interventions, and to provide clinicians with valuable 
feedback to inform their testing practices (sourced from internal document - 
minutes of three meetings of the Victorian Department of Health and Human 
Services’ Laboratory Liaison Committee).  The data to be collected by Victoria 
will be in line with that presented in Chapter 3 of this thesis. 
These actions will result in both Tasmania and Victoria meeting a number of the 
key priority actions of the National Sexually Transmissible Infections Strategy 
(1), and thereby have a positive impact on the efforts to control the chlamydia 
epidemic in those two jurisdictions.  
8.6 Conclusion 
The fundamental purpose of public health surveillance is to inform public health 
action and policy (27, 28).  Current passive surveillance of chlamydia diagnoses 
cannot meet that purpose.  This dissertation has demonstrated a new and better 
way of conducting surveillance that is achievable in Australia.  It is possible to 
collect laboratory testing data to adjust for changes in testing practices and 
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provide valuable epidemiological reports that meet public health requirements.  
The data presented in this dissertation can be used to inform policy and to 
provide advice and guidance to healthcare practitioners; and the methods ensure 
key priorities of the National Sexually Transmissible Infections Strategy are met 
(1).  
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Appendix A — Preface 
In this Appendix, I include the paper, Role of the general practitioner in testing for 
genital Chlamydia trachomatis infection: an analysis of enhanced surveillance data 
(Shaw K, Stephens N, Coleman D, O’Sullivan M) published in Sexual Health 2009, 
6, 208-212.  This paper was based on data analysed as part of the study 
described in Chapter 3 of this dissertation.  My contribution to this paper 
included all of the data analysis, contribution to the interpretation of the data 
and revision of the manuscript, contribution to the conceptualisation of the 
study, and contribution to the acquisition of the data. 
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